proline has been researched along with Chronic Hepatitis C in 768 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (0.52) | 29.6817 |
| 2010's | 660 (85.94) | 24.3611 |
| 2020's | 104 (13.54) | 2.80 |
| Authors | Studies |
|---|---|
| Flamm, SL; Martin, MT; Patel, S | 1 |
| Kakizaki, S; Kanayama, Y; Ohnishi, H; Okamoto, H; Sato, K; Suga, T; Tojima, H; Uehara, D; Uraoka, T; Yamazaki, Y; Yanagisawa, K | 1 |
| Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H | 1 |
| Feng, BL; Li, JM; Luo, JW; Naidoo, N; Wang, P; Wu, G; Xie, YX; Zhou, HJ | 1 |
| Hachisu, Y; Hatanaka, T; Hazama, Y; Kaburagi, T; Kakizaki, S; Kashiwabara, K; Murata, K; Naganuma, A; Nagashima, S; Nakano, S; Nishizawa, T; Okamoto, H; Saito, N; Takahashi, M; Tanaka, Y; Uraoka, T; Yamazaki, Y; Yoshida, S; Yoshinaga, T | 1 |
| Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L | 1 |
| Christensen, PB; Du, Y; Khera, T; Lillevang, ST; Madsen, LW; Wedemeyer, H | 1 |
| Agarwal, K; Burroughs, M; Felizarta, F; Gane, E; Hassanein, T; Krishnan, P; Nevens, F; Overcash, JS; Poordad, F; Shaw, D; Topp, A; Waters, M; Yao, BB | 1 |
| Camus, G; Grant, PM; Gupta, N; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Mukabatsinda, C; Murangwa, A; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F | 1 |
| Christensen, PB; Dröse, S; Hansen, JF; Holm, DK; Madsen, LW; Røge, BT; Øvrehus, A | 1 |
| Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD | 1 |
| Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S | 1 |
| Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ | 1 |
| Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A | 1 |
| Falade-Nwulia, O; Karimi-Sari, H; Lim, JK; Rezaee-Zavareh, MS | 1 |
| Cornberg, M; Hidde, D; Klinker, H; Lohmann, K; Lutz, T; Möller, H; Naumann, U; Simon, KG; Stoehr, A; Teuber, G | 1 |
| Chang, KC; Chang, TS; Chen, CH; Chen, WM; Chen, YH; Hsieh, YY; Hung, CH; Lu, CK; Lu, SN; Lu, YH; Tung, SY; Tung, WL; Yen, CW | 1 |
| Barclay, ST; Bradley-Stewart, A; Davis, C; Filipe, A; Fox, R; Gunson, R; MacLean, A; Ngan Chiu Bong, M; Peters, ES; Shah, R; Shepherd, SJ; Thomson, EC; Tong, L; van Vliet, VJE | 1 |
| Bair, MJ; Chang, CC; Chang, TS; Chen, CT; Chen, CY; Chen, GY; Cheng, CY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hu, JT; Huang, CF; Huang, CS; Huang, CW; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, HC; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML | 1 |
| Aghemo, A; Anolli, MP; Battistella, S; Calvaruso, V; D'Ambrosio, R; Di Marco, V; Distefano, M; Licata, A; Masarone, M; Persico, M; Petta, S; Pugliese, N; Russo, FP | 1 |
| Burroughs, M; Chayama, K; Eckert, D; Kato, K; Kumada, H; Lin, CW; Liu, W; Mensing, S; Oberoi, RK; Suleiman, AA | 1 |
| Cotter, TG; Jensen, DM | 1 |
| Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ | 1 |
| Aghemo, A; Asselah, T; Bräu, N; Brown, A; Chen, YJ; Conway, B; Grebely, J; Kleine, H; Lawitz, E; Lei, Y; Mensa, FJ; Negro, F; Pugatch, D; Puoti, M; Welzel, TM | 1 |
| Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S | 1 |
| Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V | 1 |
| de Carvalho Sampaio, H; Faria Silva, G; Fogaça, L; Magro, AJ; Nazario de Moraes, L; Perahia, D; Plana Simões, R; Targino Valente, G; Tommasini Grotto, RM; Wolf, IR | 1 |
| Ankoma-Sey, V; Bondin, M; Dos Santos, AGP; Elkhashab, M; Fontana, RJ; Lens, S; McPherson, S; Porcalla, A; Trinh, R; Xue, Z; Zeuzem, S | 1 |
| Agarwal, K; Dore, GJ; Dos Santos, AGP; Feld, JJ; Gane, E; Hezode, C; Kho, D; Klein, M; Lacombe, K; Marks, P; Martinello, M; Matthews, GV; Mercade, GE; Muir, AJ; Müllhaupt, B; Petoumenos, K; Schultz, M; Tatsch, F; Thompson, A; Wedemeyer, H | 1 |
| Alston-Smith, BL; Cohen, DE; Cramer, YS; Morse, GD; Rosenkranz, SL; Schmidt, J; Sulkowski, M; Venuto, CS; Wyles, DL | 1 |
| Abergel, A; Aguilar, H; Brown, RS; Burroughs, M; Buti, M; Carrion, BR; Chuang, WL; Chulanov, V; Cohen, E; Felizarta, F; Horváth, G; Lin, CW; Lovell, SS; Mensa, FJ; Rodrigues, L; Rodriguez-Perez, F; Schnell, G; Trinh, R; Urbánek, P; Wang, S; Zha, J; Zuckerman, E | 1 |
| Chen, DS; Chen, PJ; Hsieh, SM; Hung, CC; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Sun, HY; Tseng, TC | 1 |
| Aguilar, P; Aldámiz-Echevarría, T; Andrade, RJ; Carnicer, F; Carrión, JA; Chimeno-Hernández, S; Delgado, M; Escarda, A; Espinosa, N; Estébanez, Á; Gallego, A; García-Buey, L; Hernández-Guerra, M; Hijona, L; Izquierdo, S; Jou, A; Lorente, S; Magaz, M; Manuel Sousa, J; Manzanares, A; Martín-Granizo, I; Mateos-Muñoz, B; Menéndez, F; Morán-Sánchez, S; Morano, L; Moreno-Planas, JM; Morillas, RM; Polo-Lorduy, B; Pulido, F; Rico, M; Rincón, D; Rodríguez, M; Rubín, Á; Salmerón, J; Sampedro, B; Sánchez Antolín, G; Vergara, M; Von-Wichmann, MÁ; Zozaya, JM | 1 |
| Chayama, K; Gonzalez, YS; Kawaguchi, I; Kumada, H; Mitchell, D; Virabhak, S; Yuen, C | 1 |
| Aikata, H; Chayama, K; Hiramatsu, A; Imamura, M; Kawaoka, T; Morio, K; Murakami, E; Nakahara, T; Ohya, K; Tsuge, M; Yamauchi, M | 1 |
| Abunimeh, M; Aglitti, A; Bruchfeld, A; Flisiak, R; Jalundhwala, YJ; Kaskas, M; Lawitz, E; Mensa, FJ; Park, JY; Persico, M; Porcalla, A; Schnell, G; Sise, ME; Wörns, MA; Xue, Z; Zamor, PJ | 1 |
| Anderson, M; Caro, L; Chung, C; Fandozzi, C; Fraser, I; Gao, W; Howell, B; Mangin, E; Maxwell, J; Miltenburg, AMM; Popa, S; Railkar, R; Shire, NJ; Stoch, SA; Talal, AH; Van Dyck, K; Webber, AL; Wenning, L | 1 |
| Aschenbrenner, DS | 1 |
| Chung, RT; Holmes, JA | 1 |
| Ashraf, A; Kumar, R; Maitra, S; Singh, AD; Singh, N; Tyagi, P | 1 |
| Iliescu, EL; Mercan-Stanciu, A; Toma, L | 1 |
| Abe, H; Akahane, T; Asano, T; Atsukawa, M; Chuma, M; Fujioka, S; Fukunishi, S; Genda, T; Hiraoka, A; Iio, E; Ikeda, H; Ikegami, T; Ishikawa, T; Iwakiri, K; Kumada, T; Masaki, T; Michitaka, K; Mikami, S; Morishita, A; Moriya, A; Nakamuta, M; Nozaki, A; Ogawa, C; Okanoue, T; Okubo, H; Okubo, T; Shima, T; Shimada, N; Tachi, Y; Takaguchi, K; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsuji, K; Tsutsui, A; Uojima, H; Watanabe, T; Yamashita, N; Yasuda, S | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Lin, WT; Liu, CH; Liu, CJ; Peng, CY; Su, TH; Tseng, TC; Yang, SS | 1 |
| Akhan, S; Ergun, NC; Köse, Ş; Onlen, Y; Tatar, B; Turken, M; Yılmaz, Y | 1 |
| Cazarim, MS; Chachá, SGF; Martinelli, ALC; Pereira, LRL; Rodrigues, JPV | 1 |
| Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y | 1 |
| Aghayeva, S; Asiller, ÖÖ; Balkan, A; Çalışkan Kartal, A; Demir, M; Erarslan, E; Gülşen, MT; Güner, R; Köksal, I; Örmeci, N; Sezgin, O; Yaraş, S | 1 |
| Kwo, PY; Kwong, AJ | 1 |
| Kumar, R; Singh, AD | 1 |
| Alston-Smith, B; Anthony, DD; Balagopal, A; Cohen, DE; Morse, GD; Quinn, J; Santana-Bagur, JL; Smeaton, LM; Sulkowski, MS; Talal, AH; Venuto, CS; Vu, V; Wyles, DL | 1 |
| Bacon, B; Curry, MP; Dylla, DE; Flamm, SL; Kort, J; Marx, SE; Strezewski, J; Tsai, N; Wick, N | 1 |
| Chang, TS; Chen, CH; Chen, MY; Chen, WM; Chiu, WN; Hu, JH; Hu, TH; Hung, CH; Lu, CK; Lu, SN; Tung, SY; Wei, KL | 1 |
| Abd-Elsalam, SM; Abdulaziz, BA; El Attar, IH; El Kassas, M; Emadeldeen, M; Said, EM | 1 |
| Bajis, S; Dore, GJ; Martinello, M | 1 |
| Bernhard, B; Stickel, F | 1 |
| Alston-Smith, BL; Anthony, DD; Balagopal, A; Bhattacharya, D; Cohen, DE; Damjanovska, S; Kowal, CM; Shive, CL; Smeaton, LM; Sulkowski, MS; Wyles, DL | 1 |
| Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çelen, MK; Çelik, İ; Demirtürk, N; Ersöz, G; Karakeçili, F; Kınıklı, S; Mıstık, R; Şimşek, F; Türker, N; Turkish Society Of Clinical Microbiology And Infectious Diseases, TSGFVHOT; Ural, O; Yıldız, O; Zararsız, G | 1 |
| Fargnoli, A; Gidea, CG; Jacobson, I; Kon, Z; Lewis, T; Lonze, B; Moazami, N; Pavone, J; Qian, Y; Rao, S; Reyentovich, A; Saraon, T; Smith, D | 1 |
| Abergel, A; Asselah, T; Fredrick, LM; Gane, E; George, C; Hung Le, M; Kowdley, KV; Kwo, PY; Lee, SS; Mensa, F; Nguyen, K; Nguyen, T; Pham, TT; Poordad, F; Schnell, G; Spearman, CW; Wong, F; Yao, BB | 1 |
| Hsu, EK; Jolley, CD; Jonas, MM; Leung, DH; Liu, L; Lobritto, SJ; Molleston, JP; Narkewicz, MR; Rosenthal, P; Wen, J; Yao, BB; Zha, J | 1 |
| Altıntaş, E; Ateş, F; Özdoğan, O; Sezgin, O; Üçbilek, E; Yaraş, S | 2 |
| Abufreha, N; Dahari, H; Dizengof, V; Etzion, O; Nevo-Shor, A; Yardeni, D | 1 |
| Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH | 1 |
| Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO | 1 |
| Caruntu, F; Cohen, S; de Ledinghen, V; Dillon, JF; Dylla, DE; Fredrick, LM; Gschwantler, M; Gutierrez, JA; Muir, AJ; Nevens, F; Pires Dos Santos, AG; Puoti, M; Rodrigues, L; Sigal, S; Slim, J; Zuckerman, E | 1 |
| Alami, NN; Asatryan, A; Burroughs, M; Fredrick, LM; Heo, J; Hou, J; Jia, J; Kalluri, HV; Kim, YJ; Krishnan, P; Lim, SG; Liu, W; Lu, W; Mobashery, N; Tripathi, R; Wang, G; Wei, L; Xie, Q; Xie, W; Zhang, M | 1 |
| Barclay, ST; Belperio, PS; Bondin, M; Flamm, S; Lampertico, P; Lohmann, K; Marra, F; Marx, S; Mauss, S; Persico, M; Wedemeyer, H; Zhang, Z | 1 |
| Chen, YY; Chou, KC; Hsu, YC; Huang, SP; Liu, IL; Su, PY; Wu, SS; Yang, CW; Yen, HH; Zeng, YH | 1 |
| Bani-Sadr, F; Bourlière, M; Carrat, F; Chalouni, M; de Ledinghen, V; Dorival, C; Esterle, L; Fontaine, H; Lacombe, K; Larrey, D; Marc-Lacombe, J; Pol, S; Salmon, D; Sogni, P; Wittkop, L; Zucman, D | 1 |
| Rodriguez-Reyes, M; Ruiz-Boy, S; Sotoca-Momblona, JM | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Cho, M; Heo, J; Hong, YM; Kim, DU; Kim, GH; Kim, HH; Park, SG; Park, YJ; Song, GA; Woo, HY; Yoon, KT | 1 |
| Chen, CH; Hsu, CS; Hsu, YC; Hui, YT; Kan, YM; Li, MKK; Liu, CH; Liu, KSH; Tsai, MC; Wong, GLH; Yap, DYH; Yu, ML; Yuen, MF | 1 |
| Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A | 1 |
| Cornberg, M; Deterding, K; Jung, MC; Klinker, H; Manns, MP; Sarrazin, C; Schulze Zur Wiesch, J; Serfert, Y; Simon, KG; Stoehr, A; Teuber, G; Vermehren, J; Wedemeyer, H; Zeuzem, S | 1 |
| Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S | 1 |
| Jiang, X; Xu, Y; Zhang, Y; Zhao, Y | 1 |
| Dronamraju, D; Kwo, P | 1 |
| Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L | 1 |
| Abd-Elsalam, S; Abo-Amer, YE; Ahmed, R; Badawi, R; El-Abgeegy, M; Elguindy, AMA; Elkadeem, M; Elsergany, HF; Elshweikh, SA; Hawash, N; Mansour, L; Mohmed, AA; Soliman, MY; Soliman, S | 1 |
| Hernandez, C; Hezode, C; Mangia, A; Turnes, J | 1 |
| Singh, AD | 1 |
| Berak, H; Białkowska-Warzecha, J; Buczyńska, I; Citko, J; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Sobala-Szczygieł, B; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D; Łapiński, TW | 1 |
| Crehuá Gaudiza, E; Quintero García, D; Sebastián Cuevas, FJ | 1 |
| Biliotti, E; Cruciata, A; Mezzaroma, I; Milito, C; Rivano Capparuccia, M; Spaziante, M; Taliani, G; Volpicelli, L | 1 |
| Chen, HW; Hsieh, CB; Hsieh, TY; Lin, JC | 1 |
| Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YK; Wang, YW | 1 |
| Clerc, O; Magenta, L; Müllhaupt, B; Negro, F; Ruckstuhl, L; Semela, D; Semmo, N; Torgler, R | 1 |
| Buonomo, AR; Cattaneo, L; Coppola, C; Coppola, N; De Pascalis, S; Gentile, I; Martini, S; Mercinelli, S; Messina, V; Nerilli, M; Pinchera, B; Scotto, R; Staiano, L; Stanzione, M; Stornaiuolo, G | 1 |
| Erren, P; König, B; Lohmann, K; Mauss, S; Naumann, U; Rieke, A; Stoehr, A; Wedemeyer, H; Zimmermann, T | 1 |
| Hara, T; Iwai, N; Kagawa, K; Komaki, T; Nagata, A; Ohara, T; Oka, K; Okuda, T; Sakagami, J; Sakai, H; Taniguchi, M; Tsuji, T | 1 |
| Akarca, US; Akarsu, M; Akbulut, S; Akın, M; Aladağ, M; Albayrak, B; Alkım, H; Atalay, R; Balkan, A; Balkan, Y; Çoban, M; Coşar, AM; Danış, N; Değertekin, B; Demir, M; Demircan, M; Dinçer, D; Doğanay, L; Dursun, H; Erarslan, E; Göktürk, HS; Gündüz, F; Güneş, Ş; Gürel, S; Güzelbulut, F; Harputluoğlu, M; İnci, İ; Irak, K; Kaçar, S; Kani, HT; Kartal, A; Kefeli, A; Koklu, H; Mert, A; Nuriyev, K; Özakyol, A; Özdoğan, O; Öztaşkın, S; Sen, İ; Şimşek, H; Soylu, A; Sümer, H; Temel, T; Üçbilek, E; Uğurlu, ÇB; Uyanıkoğlu, A; Vatansever, S; Yalçın, K; Yaras, S; Yıldırım, E | 1 |
| Booth, J; Borgia, SM; Conway, B; Cooper, C; Feld, JJ; Lee, S; Lilly, LB; Morales, H; Onofrio, FQ; Ramji, A; Sattar, I; Vachon, ML; Wong, A | 1 |
| Fedorchenko, SV; Klimenko, Z; Martynovych, T; Solianyk, I | 1 |
| Buti, M; Campos, C; Cañizares, A; Carrión, JA; Castro-Iglesias, A; Costa, JG; Esteban, JI; Garcia-Cehic, D; Gregori, J; Macenlle, R; Pamplona, J; Quer, J; Rando, A; Rodriguez-Frias, F; Tabernero, D | 1 |
| Baroiu, L; Cijevschi, C; Diculescu, M; Gheorghe, L; Iliescu, L; Luca, MC; Miftode, E; Mihai, C; Pojoga, C; Sparchez, ZA; Sporea, I; Stanciu, C; Streinu-Cercel, A; Trifan, A | 1 |
| Berg, T; Bondin, M; Cornberg, M; Klinker, H; Koenig, B; Lohmann, K; Naumann, U; Rössle, M; Zeuzem, S | 1 |
| Bourlière, M; Meszaros, M; Ouzan, D; Pageaux, GP; Tran, A; Truchi, R | 1 |
| Bondin, M; Brown, A; Burroughs, M; Chayama, K; Dylla, DE; Emmett, A; Feld, JJ; Forns, X; Gordon, SC; Heo, J; Hou, J; Jacobson, IM; Lampertico, P; Marcinak, J; Pol, S; Tatsch, F; Zhang, Z | 1 |
| Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S | 1 |
| Adachi, T; Akashi, H; Akutsu, N; Ban, T; Hirano, T; Ishigami, K; Isshiki, H; Kaneto, H; Matsui, T; Nakachi, K; Nakahara, S; Nakase, H; Numata, Y; Sasaki, S; Takagi, H; Tanaka, K; Tsujisaki, M; Wagatsuma, K; Yamamoto, I; Yamaoka, S; Yawata, A; Yonezawa, K | 1 |
| Ahmed, M; Gomaa, AA; Mansey, AE; Rabea, HM; Wahsh, EA | 1 |
| Alami, NN; Asatryan, A; Bae, SH; Cho, M; Crown, ED; Fredrick, LM; Han, KH; Heo, J; Jeong, SH; Kim, DH; Kim, JH; Kim, YJ; Lee, JW; Lee, YJ; Lim, YS; Paik, SW; Yoon, KT | 1 |
| Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y | 1 |
| Andrade, RJ; Calleja, JL; Calvo, M; Delgado, MB; Frias, YN; Gálvez-Fernández, RM; Gómez, J; López, MA; Manzano, ML; Molina, E; Olveira, A; París, S; Rincón, D; Rosales, JM; Salmerón, FJ; Santos de Lamadrid, R; Turnes, J; Vallejo-Senra, N | 1 |
| Bukh, J; Christensen, PB; Fahnøe, U; Madsen, LW; Pedersen, MS; Øvrehus, A | 1 |
| Darling, JM; Di Bisceglie, A; Dong, M; Evon, DM; Fishbein, DA; Fried, MW; Hinestrosa, F; Horne, PM; Khalili, M; Kixmiller, S; Lok, AS; Michael, L; Moon, JS; Morelli, G; Muir, AJ; Nelson, DR; Pearlman, B; Peter, J; Rajender Reddy, K; Segal, JB; Sherman, KE; Shiffman, ML; Sloan, A; Stewart, PW; Sulkowski, MS; Vainorius, M; Wadsworth, S | 1 |
| Al Abosy, R; Allen, TM; Chung, RT; Comstock, DE; Fidler, S; Fox, J; Frater, J; Gerdemann, U; Haining, WN; Kim, AY; Lauer, GM; Martin, GE; Sen, DR; Tonnerre, P; Tully, DC; Weiss, SA; Wolski, D; Yates, KB | 1 |
| Ichijo, T; Joshita, S; Kawakami, F; Kobayashi, H; Nakazawa, H; Sugiura, A; Umemura, T; Wakabayashi, SI; Yamashita, Y; Yamazaki, T | 1 |
| Ahmed, S; Ajaimy, M; Campbell, A; Graham, JA; Jorde, UP; Nnani, DU; Patel, SR; Saeed, O | 1 |
| Barclay, ST; Burroughs, M; Calleja, JL; de Ledinghen, V; Dylla, DE; Gane, E; Gutierrez, JA; Rizzardini, G; Shiffman, ML; Xue, Z | 1 |
| Flisiak, R; Flisiak-Jackiewicz, M | 1 |
| Baumgarten, A; Berg, T; Buggisch, P; Christensen, S; Deterding, K; Hettinger, J; Heyne, R; Hinrichsen, H; Hüppe, D; John, C; Kleine, H; König, B; Lutz, T; Mauss, S; Sarrazin, C; Schott, E; Stein, K; Teuber, G; van Bömmel, F; Wedemeyer, H; Welzel, TM; Zimmermann, T | 1 |
| Bourlière, M; Carrat, F; Carrieri, MP; Fontaine, H; Hézode, C; Marcellin, F; Petrov-Sanchez, V; Protopopescu, C; Vilotitch, A; Younossi, Z | 1 |
| Cheng, K; Chevaliez, S; Cloherty, G; Cohen, DE; Dawson, GJ; Feld, JJ; Hackett, J; Herman, C; Maasoumy, B; Pawlotsky, JM; Rockstroh, JK; Sarrazin, C; Wedemeyer, H | 1 |
| Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N | 1 |
| Agarwal, K; Asselah, T; Berg, T; Bhandari, BR; Borgia, SM; Brainard, DM; Bräu, N; Davis, M; Dore, GJ; Dvory-Sobol, H; Feld, JJ; Foster, GR; Gane, EJ; Hyland, RH; Jacobson, IM; Lawitz, E; McHutchison, JG; Nahass, RG; Pearlman, B; Roberts, SK; Ruane, PJ; Shafran, SD; Stamm, LM; Stedman, CAM; Subramanian, GM; Svarovskaia, E; Thompson, AJ; Willems, BE; Workowski, KA; Zhu, Y | 1 |
| Asselah, T; ElKhashab, M; Feld, JJ; Ferenci, P; Hassanein, T; Hézode, C; Mobashery, N; Moreno, C; Papatheodoridis, G; Pilot-Matias, T; Qaqish, RB; Redman, R; Yu, Y; Zeuzem, S | 1 |
| Allam, N; Asselah, T; Doss, W; Esmat, G; Hall, C; Hassany, M; Mobashery, N; Mohey, MA; Qaqish, RB; Redman, R; Shiha, G; Soliman, R; Waked, I; Yosry, A; Zayed, N | 1 |
| Agarwal, K; Aguilar, H; Asatryan, A; Dore, GJ; Felizarta, F; Gane, E; Gordon, SC; Hassanein, T; Kort, J; Kwo, PY; Lin, CW; Liu, R; Lovell, SS; Maliakkal, B; Mensa, FJ; Muir, AJ; Ng, TI; Overcash, JS; Poordad, F; Sulkowski, MS; Wang, S; Wyles, DL | 1 |
| Asselah, T; Cohen, DE; Dumas, EO; Feld, JJ; Forns, X; Hazzan, R; Lu, W; Pilot-Matias, T; Shaw, D; Welzel, TM; Zeuzem, S | 1 |
| Gray, E; Norris, S; O'Leary, A; Pasta, DJ | 1 |
| Chan, HL; Lo, AO; Wong, GL; Wong, VW | 1 |
| Al Marzooqi, SH; Cerocchi, O; Duarte-Rojo, A; Feld, JJ; Harrell, SM; Janssen, HLA; Karkada, J; Klair, JS; Kowgier, M; Maan, R; Rhodes, KD | 1 |
| Aghemo, A; Alberti, A; Antinori, A; Ascione, A; Bruno, R; Bruno, S; Chirianni, A; Craxì, A; Gaeta, GB; Giannini, EG; Marzioni, M; Merli, M; Messina, V; Montilla, S; Pani, L; Perno, CF; Petta, S; Puoti, M; Raimondo, G; Rendina, M; Russo, P; Silberstein, FC; Villa, E; Zignego, AL | 1 |
| Ceccherini-Silberstein, F; Cento, V; Cuypers, L; Di Maio, VC; Libin, P; Lunar, MM; Nevens, F; Nowé, A; Poljak, M; Schrooten, Y; Theys, K; Van Laethem, K; Vandamme, AM | 1 |
| Czarny, P; Jabłkowski, M; Karwowski, B; Majchrzak, K; Merecz-Sadowska, A; Śliwiński, T; Szemraj, J | 1 |
| Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H | 1 |
| Aikata, H; Chayama, K; Daijo, K; Hayes, CN; Honda, F; Honda, Y; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Miki, D; Mori, N; Morio, K; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Takaki, S; Teraoka, Y; Tsuge, M; Tsuji, K | 1 |
| Álvares-Da-Silva, MR; Brandão-Mello, CE; Callefi, LA; Carnaúba-Júnior, D; Chachá, SGF; Coelho, HSM; de Barros Tenore, S; de Lourdes Candolo Martinelli, A; de Macedo Bisio, AP; de Mello Perez, R; de Souza Paiva Ferreira, A; Ferraz, MLCG; Ferreira, PRA; Ivantes, CAP; Mendes-Correa, MCJ; Nabuco, LC; Pessoa, MG; Pinto, PTA; Reuter, T; Villela-Nogueira, CA | 1 |
| Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Lin, KH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Jacobson, IM; Voaklander, R | 1 |
| Ashur, Y; Balicer, R; Braun, M; Brufman, I; Hammerman, A; Hoshen, M; Leventer-Roberts, M; Lieberman, N | 1 |
| Antón, MD; Ferrando, I; Latorre, P; Moreno Osset, E; Pascual, A; Polanco, A | 1 |
| Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 1 |
| Asatryan, A; Campbell, A; Ding, B; Dutta, S; Kort, J; Lin, CW; Liu, W; Podsadecki, T; Wang, T; Zadeikis, N | 1 |
| Asatryan, A; Geoffroy, P; Kort, J; Kosloski, MP; Liu, W; Zhao, W | 1 |
| Dammermann, W; Dettmann, I; Komorowski, L; Lüth, S; Mindorf, S; Polywka, S; Schulze Zur Wiesch, J; Stöcker, W; Wehmeyer, M | 1 |
| Alves, K; Beyer, J; Burroughs, M; Chayama, K; Collins, C; Dekhtyar, T; Irvin, M; Krishnan, P; Kumada, H; Pilot-Matias, T; Redman, R; Reisch, T; Rodrigues, L; Schnell, G; Setze, C; Tripathi, R | 1 |
| Alves, K; Atarashi, T; Atsukawa, M; Burroughs, M; Chayama, K; Fu, B; Kato, K; Kumada, H; Naganuma, A; Nakamuta, M; Notsumata, K; Oberoi, RK; Osaki, Y; Pilot-Matias, TJ; Pugatch, D; Redman, R; Saito, S; Sato, K; Suzuki, F; Takaguchi, K; Toyoda, H; Watanabe, T | 1 |
| Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Loutfy, SA; Menshawy, A; Mohamed, A; Negida, A | 1 |
| Abou-Samra, AB; Butt, AA; Simon, TG; Yan, P | 1 |
| Agarwal, K; Alric, L; Felizarta, F; Hassanein, T; Kort, J; Krishnan, P; Kwo, PY; Lee, SS; Lin, CW; Liu, R; Lovell, SS; Maliakkal, B; Mensa, FJ; Pilot-Matias, T; Poordad, F; Wang, S; Weilert, F; Wyles, D | 1 |
| Lamb, YN | 1 |
| Cole, J; Stark, JE | 1 |
| Alves, K; Atarashi, T; Burroughs, M; Chayama, K; Eguchi, Y; Karino, Y; Kato, K; Kawakami, Y; Krishnan, P; Kumada, H; Naganuma, A; Oberoi, RK; Pilot-Matias, TJ; Pugatch, DL; Redman, R; Sato, K; Seike, M; Suzuki, F; Takei, Y; Watanabe, T; Xie, W; Yoshiji, H | 1 |
| Agarwal, K; Aguilar, H; Asselah, T; Calinas, F; Colombo, M; de Ledinghen, V; Elkhashab, M; Hassanein, T; Hezode, C; Horsmans, Y; Kort, J; Kowdley, KV; Krishnan, P; Lin, CW; Liu, R; Mantry, PS; Marinho, RT; Mensa, FJ; Nevens, F; Ng, TI; Wang, S; Zadeikis, N | 1 |
| Fauler, G; Kessler, HH; Leber, B; Mangge, H; Posch, A; Rainer, F; Spindelboeck, W; Stadlbauer, V; Stauber, RE; Streit, A | 1 |
| Ardèvol, M; Carrión, JA; Gallego, A; González-Colominas, E; Lens, S; Londoño, MC; López, D; Mariño, Z; Mojal, S; Morillas, RM; Pagès, N; Solà, R; Torras, X | 1 |
| Abraham, GM; Spooner, LM | 1 |
| Bräu, N; Brown, A; Collins, C; Colombo, M; Gane, E; Kosloski, M; Lawitz, E; Lei, Y; Leroy, V; Mensa, FJ; Moreno, C; Nelson, DR; Papatheodoridis, G; Persico, M; Pol, S; Pugatch, D; Yoshida, EM | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K | 1 |
| Agrati, C; Ammassari, A; Antinori, A; Bellagamba, R; Fabbri, G; Libertone, R; Lupi, F; Mastrorosa, I; Notari, S; Tempestilli, M; Timelli, L; Zaccarelli, M | 1 |
| Kottilil, S; O'Brien, TR; Pfeiffer, RM | 1 |
| Asatryan, A; Bernstein, DE; Buti, M; Felizarta, F; Fried, MW; Gallant, J; Gordon, SC; Hézode, C; Kopecky-Bromberg, S; Kort, J; Krishnan, P; Lei, Y; Lin, CW; Mensa, FJ; Ng, TI; Pianko, S; Pol, S; Poordad, F; Reindollar, RW; Shaw, D | 1 |
| Bourliere, M; Cooper, C; Flamm, S; Gordon, S; Hunt, S; Jacobson, I; Kowdley, K; Mann, MP; Reddy, KR; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
| Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG | 1 |
| Beyer, J; Burroughs, M; Chayama, K; Collins, C; Dekhtyar, T; Fu, B; Irvin, M; Krishnan, P; Kumada, H; Pilot-Matias, T; Redman, R; Reisch, T; Schnell, G; Tripathi, R; Xie, W | 1 |
| Asselah, T; Foster, GR; Gane, EJ; Henry, L; Jacobson, IM; Lawitz, E; Pearlman, B; Racila, A; Roberts, SK; Stepanova, M; Thompson, AJ; Welzel, TM; Willems, BE; Younossi, I; Younossi, ZM | 1 |
| Hubbard, H; Lawitz, E | 1 |
| Komatsu, H; Miyata, N; Tachikawa, N; Yoshimura, Y | 1 |
| Chen, C; Hartigan-O'Connor, DJ; Khalili, M; Lanier, LL; Lu, D; Manos, MM; McCune, JM; Méndez-Lagares, G; Monto, A; Ryan, JC; Segal, MR; Shen, H; Terrault, N | 1 |
| Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI | 1 |
| Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM | 1 |
| Chamorro-de-Vega, E; De Lorenzo-Pinto, A; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz-Alonso, A; Iglesias-Peinado, I; Rodriguez-Gonzalez, CG; Sanjurjo Saez, M | 1 |
| Younossi, ZM | 1 |
| Danta, M; Sanagapalli, S | 1 |
| Chen, CY; Chen, MY; Chen, Q; Kao, JH; Peng, CY; Tang, H; Wu, JJ; Yu, ML | 1 |
| Asatryan, A; Asselah, T; Bourlière, M; Bruck, R; Chuang, WL; Dore, GJ; Feld, JJ; Felizarta, F; Flamm, S; Flisiak, R; Foster, GR; Fu, B; Fuster, F; Gane, E; Kaita, K; Kort, J; Kwo, P; Lin, CW; Liu, R; Mensa, FJ; Ng, TI; Paik, SW; Pilot-Matias, T; Pol, S; Poordad, F; Puoti, M; Roberts, SK; Ruane, PJ; Sepulveda-Arzola, G; Soto-Malave, R; Stedman, CA; Tam, E; Trinh, R; Vargas, HE; Vierling, J; Wang, S; Wedemeyer, H; Zeuzem, S | 1 |
| Bataga, S; Brisc, C; Caruntu, FA; Chiriac, S; Cijevschi Prelipcean, C; Curescu, M; Gheorghe, L; Girleanu, I; Goldis, A; Iacob, S; Miftode, E; Mihai, C; Preda, C; Rogoveanu, I; Singeap, AM; Sporea, I; Stanciu, C; Stefanescu, G; Trifan, A | 1 |
| Borba, HHL; Ferreira, VL; Leonart, LP; Pontarolo, R; Tonin, FS | 1 |
| Debes, JD; Singh, D | 1 |
| Aghemo, A; Baldanti, F; Borghi, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Lampertico, P; Lunghi, G; Novazzi, F; Paolucci, S; Perbellini, R | 1 |
| Caroprese, M; Coppola, N; De Pascalis, S; Guerrera, B; Iovinella, V; Macera, M; Masarone, M; Minichini, C; Occhiello, L; Starace, M; Vitrone, M | 1 |
| Deeks, ED; Heo, YA | 1 |
| Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, M | 1 |
| Chang, TT; Dufour, JF; Foster, GR; Gane, E; Gordon, SC; Hezode, C; Lee, SS; Lovell, S; Marinho, R; Mensa, FJ; Moreno, C; Mutimer, D; Pilot-Matias, T; Pol, S; Puoti, M; Strasser, SI; Thuluvath, PJ; Wang, S; Zhang, Z | 1 |
| Alcaro, S; Artese, A; Barreca, GS; De Siena, M; Di Salvo, S; Fabiani, F; Focà, A; Giancotti, F; Gravina, T; Liberto, MC; Marano, V; Marascio, N; Pavia, G; Perrotti, N; Reale, M; Romeo, I; Talarico, C; Torti, C | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Kuwano, T; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Beyer, J; Collins, C; Dekhtyar, T; Hall, C; Irvin, M; Krishnan, P; Mobashery, N; Pilot-Matias, T; Redman, R; Reisch, T; Schnell, G; Tripathi, R; Yu, Y | 1 |
| Cory, TJ; Gong, Y; Kodidela, S; Kumar, S; Mu, Y | 1 |
| Hashimoto, S; Hayashi, K; Nakagawa, Y; Saito, K; Takahashi, K; Takamura, M; Takeuchi, S; Tanabe, Y; Tasaki, M; Terai, S; Tomita, Y; Yamagiwa, S; Yoshida, T | 1 |
| Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J | 1 |
| Agarwal, K; Angus, P; Brown, RS; Dumas, EO; Forns, X; Gane, E; Gulati, A; Hu, YB; Kao, JH; Krishnan, P; Kwo, PY; Liu, W; Mantry, PS; Mutimer, D; Porcalla, A; Reau, N; Reddy, KR; Rhee, S; Samanta, S; Shulman, NS; Tran, TT; Trinh, R | 1 |
| Bogomolov, PO; Chen, X; Enejosa, JV; Isakov, V; Maevskaya, MV; Ogurtsov, P; Paduta, D; Pasechnikov, V; Shulman, NS; Viani, RM; Znoyko, O | 1 |
| Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Nozawa, Y; Owaki, T; Sano, T; Sato, H; Seki, K; Yoshida, T | 1 |
| Abe, K; Hoshino, T; Kawakami, T; Miyasaka, A; Murakami, A; Ohuchi, K; Sawara, K; Takikawa, Y; Watanabe, D; Yoshida, T; Yoshida, Y | 1 |
| Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL | 1 |
| Abutaleb, A; Kottilil, S; Wilson, E | 1 |
| Waked, I | 1 |
| Bourlière, M; Brainard, DM; Curry, MP; Dvory-Sobol, H; Gordon, SC; Hyland, RH; Landis, CS; Manns, MP; McHutchison, JG; Ravendhran, N; Reddy, KR; Schiff, ER; Sepe, TE; Serfaty, L; Stamm, LM; Subramanian, GM; Thompson, AJ; Tran, TT; Zhang, J | 1 |
| Dolman, GE; Gelson, WT; Selby, P | 1 |
| Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M | 1 |
| Bourliere, M; Gordon, SC; Manns, MP; Racila, A; Reddy, R; Schiff, E; Stepanova, M; Tran, T; Younossi, I; Younossi, ZM | 1 |
| Alami, NN; Allam, N; Esmat, G; Fouad, R; Hall, C; Hassany, M; Kopecky-Bromberg, S; Mobashery, N; Mohey, M; Qaqish, RB; Shiha, G; Soliman, R; Waked, I | 1 |
| Alves, K; Ding, B; Luo, Y; Menon, RM; Mobashery, N; Wang, H; Yu, C; Zha, J; Zhao, W | 1 |
| Cerban, R; Ester, C; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Pietrareanu, C; Popescu, I | 1 |
| Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M | 1 |
| Blatt, CR; Carneiro, JMM; Chachá, SGF; Farias, MR; Feltrin, AA; Gomes, LO; Martinelli, ALC; Noblat, LACB; Pereira, LRL; Rodrigues, JPV; Rosa, JAD; Silveira, MPT; Teixeira, MR; Vecchi, MD | 1 |
| Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N | 1 |
| Arai, K; Honda, M; Horii, R; Iida, N; Kaneko, S; Kawaguchi, K; Kitahara, M; Kitamura, K; Mizukoshi, E; Nio, K; Orita, N; Sakai, Y; Shimakami, T; Sunagozaka, H; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Beyer, J; Collins, C; Dekhtyar, T; Irvin, M; Krishnan, P; Larsen, L; Mensa, FJ; Ng, TI; Pilot-Matias, T; Reisch, T; Schnell, G; Tripathi, R; Xie, W | 1 |
| Ellis, S | 1 |
| Nehra, V; Rizza, SA; Temesgen, Z | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Bourliere, M; Brainard, DM; Camus, G; Cooper, CL; Doehle, BP; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Hyland, RH; Kowdley, KV; Manns, MP; Martin, R; Mo, H; Reddy, KR; Roberts, SK; Sarrazin, C; Stamm, LM; Svarovskia, E; Zeuzem, S | 1 |
| Keam, SJ; Markham, A | 1 |
| Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CY; Lin, SM; Sheen, IS; Tai, DI; Teng, W | 1 |
| Asatryan, A; Beyer, J; Campbell, A; Collins, C; Dekhtyar, T; Irvin, M; Kort, J; Krishnan, P; Lawitz, EJ; Lovell, S; Lu, L; Mensa, F; Ng, TI; Pilot-Matias, T; Reisch, T; Schnell, G; Tripathi, R; Yao, B | 1 |
| Antón, MD; Badia, E; Cabezas, J; Calleja, JL; Carrión, JA; Castro, JL; Cordero, P; De Cuenca, B; De la Vega, J; Diago, M; Gea, F; Lens, S; Molina, E; Montoliu, S; Moreno, J; Moreno, JM; Morillas, RM; Olveira, A; Pascasio, JM; Puigvehí, M; Salmerón, J; Sánchez-Ruano, JJ; Torras, X; Turnes, J; Viu, A | 1 |
| Abdel-Aziz, EM; Abdel-Malek, MO; Hashim, AA; Hetta, HF; Mekky, MA; Morsy, KH; Osman, HA | 1 |
| Beyer, J; Collins, C; Dekhtyar, T; Irvin, M; Krishnan, P; Lu, L; Ng, TI; Pilot-Matias, T; Reisch, T; Schnell, G; Tripathi, R; Xie, W | 1 |
| Hinds, AE; Pearlman, BL | 1 |
| Lee, TY; Yang, SS | 1 |
| Fabrizi, F; Messa, P | 1 |
| Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Hiramatsu, A; Imamura, M; Kawaoka, T; Miki, D; Morio, K; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| Eibl, MM; Müller, CJ; Wolf, HM | 1 |
| Erlich, DR; Grover, A | 1 |
| Applegate, TL; Bruggmann, P; Bruneau, J; Castro, E; Conway, B; Cooper, C; Crawford, S; Cunningham, EB; Dalgard, O; Daulouede, JP; Dore, GJ; Dunlop, A; Erratt, A; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Kronborg, I; Lacombe, K; Marks, P; Matthews, GV; Moriggia, A; Petoumenos, K; Powis, J; Schmid, P; Shaw, D; Stedman, C | 1 |
| Abergel, A; Asselah, T; Gane, E; Lee, SS; Lim, SG; Mahomed, A; Mensa, FJ; Nguyen, K; Nguyen, T; Porcalla, A; Sasadeusz, J; Schnell, G; Wong, F; Yao, BB; Zadeikis, N; Zhang, Z | 1 |
| Agarwal, K; Asatryan, A; Flamm, S; Gane, E; Heo, J; Horsmans, Y; Kopecky-Bromberg, S; Krishnan, P; Kwo, PY; Lovell, SS; Mensa, FJ; Mutimer, D; Ng, TI; Rockstroh, J; Ruane, PJ; Ryder, SD; Trinh, R; Villa, E; Wang, S; Weiland, O; Welzel, TM; Wyles, DL; Xue, Z | 1 |
| Caroleo, B; Caroleo, MC; Cimellaro, A; Colangelo, L; De Sarro, G; Di Mizio, G; Gallelli, L; Perticone, M | 1 |
| Adamek, B; Baka-Ćwierz, B; Belica-Wdowik, T; Berak, H; Białkowska-Warzecha, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracki, W; Dybowska, D; Flisiak, R; Garlicki, A; Gietka, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Laurans, Ł; Lorenc, B; Mazur, W; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D | 1 |
| Baba, M; Izumi, T; Kawagishi, N; Kimura, M; Maehara, O; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
| Alatrakchi, N; Brown, J; Carlton-Smith, C; Chung, RT; Cohen, DE; Dumas, EO; Gustafson, JL; Holmes, JA; Kim, AY; Kvistad, D; Lauer, GM; Robidoux, M; Shulman, NS; Silva, ST; Tonnerre, P; Zhang, H | 1 |
| Bondin, M; Cacoub, P; Fabrizi, F; Negro, F | 1 |
| Cenderello, G; Di Biagio, A; Taramasso, L | 1 |
| Li, K; Liu, JP; Ning, HB; Shang, J; Xiao, EH | 1 |
| Liu, W; Lovell, S; Mensa, FJ; Pilot-Matias, T | 1 |
| Aghemo, A; Lleo, A; Plaz Torres, MC | 1 |
| Aguilar, H; Asatryan, A; Asselah, T; Baumgarten, A; Conway, B; Dore, GJ; Foster, GR; Grebely, J; Gschwantler, M; Hu, Y; Jackson, D; Mensa, FJ; Sherman, KE; Tomasiewicz, K; Wang, S | 1 |
| Chuang, WL; Crawford, DHG; Dokmeci, AK; Hamid, SS; Ibrahim, A; Jindal, A; Kanda, T; Kao, JH; Kumar, M; Lau, GKK; Lesmana, CRA; McCaughan, GW; Moriyama, M; Omata, M; Sarin, SK; Sharma, BC; Sollano, J; Wasim, J; Wei, L; Yokosuka, O; Yu, ML | 1 |
| Baba, M; Kawagishi, N; Kimura, M; Maehara, O; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
| Affonso-de-Araújo, ES; Álvares-da-Silva, MR; Alves, K; Brandão-Mello, CE; Cheinquer, H; Coelho, HS; Cohen, DE; Ferraz, ML; Ferreira, PRA; Furtado, J; Lari, SA; Liu, L; Martinelli, A; Mendes-Correa, MC; Nunes, EP; Parana, R; Pessoa, MG; Pilot-Matias, T; Ramalho-Madruga, JV; Shulman, NS; Silva, G; Tripathi, R | 1 |
| Asatryan, A; Asselah, T; Foster, GR; Kopecky-Bromberg, S; Lei, Y; Mensa, FJ; Trinh, R; Zadeikis, N | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H | 1 |
| Fan, H; Fu, Z; Huang, P; Tian, T; Wang, Y; Wu, J; Xia, X; Ye, X; Yue, M; Zhang, Y | 1 |
| Brainard, DM; Dvory-Sobol, H; Gane, EJ; Hyland, RH; Nyberg, L; Ruane, P; Shafran, S; Shao, J; Stamm, LM; Strasser, SI; Tran, T | 1 |
| Asiller, ÖÖ; Ateş, K; Aygen, B; Erdem, İ; Karaali, R; Karakaya, F; Örmeci, N; Sezgin, O; Turan, D; Yaras, S; Yildiz, O | 1 |
| Althoff, CE; Bergfeld, L; Brakemeier, S; Budde, K; Duerr, M; Eckardt, KU; Glander, P; Halleck, F; Lehner, LJ; Marticorena Garcia, SR; Sack, I; Schrezenmeier, EV | 1 |
| Boyacıoğlu, AS; Çolak, T; Dağlı, Ü; Haberal, M; Hilmioğlu, F; Öcal, S; Özer Etik, D; Selçuk, H; Suna, N | 1 |
| Camus, G; Dvory-Sobol, H; Han, B; Hsieh, D; Lu, J; Martin, R; Mo, H; Parhy, B; Svarovskaia, ES | 1 |
| Back, D; Bondin, M; Bourgeois, S; Buggisch, P; Charafeddine, M; Crown, E; Curescu, M; Dorr, P; Ferenci, P; Flisiak, R; Kleine, H; Larrey, D; Marra, F; Norris, S | 1 |
| Dabes, H; ElSaeed, K; ElSerafy, M; ElShazly, Y; Hamed, S; Omar, H; Saad, Y; Said, M; Soliman, Z | 1 |
| Abunimeh, M; Bennett, M; Cohen, DE; Cohen, E; Everson, G; Phillips, RW; Pilot-Matias, T; Poordad, F; Reindollar, RW; Sepe, TE; Siddique, A; Sullivan, JG; Younes, Z | 1 |
| Abe, H; Aizawa, Y; Akahane, T; Atsukawa, M; Fukunishi, S; Genda, T; Hotta, N; Ikegami, T; Iwakiri, K; Kondo, C; Kumada, T; Michitaka, K; Nakamuta, M; Nozaki, A; Ogawa, C; Shima, T; Shimada, N; Tachi, Y; Takaguchi, K; Tanaka, Y; Toyoda, H; Tsubota, A; Tsuji, K; Uojima, H; Watanabe, T | 1 |
| Kiser, JJ | 1 |
| Asatryan, A; Elkhashab, M; Gane, E; Greenbloom, S; Lin, CW; Liu, W; Mensa, FJ; Mulkay, JP; Nguyen, T; Pilot-Matias, T; Poordad, F; Porcalla, A; Setze, C; Stedman, C; Tran, A; Valdes, J; Wang, S; Wörns, MA; Yu, Y; Zadeikis, N | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, YC; Lu, SN; Wang, JH | 1 |
| Afify, S; Alboraie, M; Algaber, MA; Doss, W; El Halwagy, H; El Kassas, M; El Latif, YA; El Tahan, A; Elsaeed, K; Elserafy, M; Omar, H | 1 |
| Bukh, J; Dietz, J; Fahnøe, U; Filskov, J; Fourati, S; Ghanem, L; Gottwein, JM; Humes, D; Jensen, SB; Krarup, H; Pawlotsky, JM; Pedersen, MS; Pham, LV; Pihl, AF; Ramirez, S; Sarrazin, C; Schønning, K; Serre, SBN; Sølund, CS; Tang, Q; Weis, N | 1 |
| Back, D; Belperio, P; Bondin, M; Crown, E; Marra, F; Mensa, FJ; Negro, F; Park, C; Pinsky, B; Talal, AH; Zhang, Z | 1 |
| Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K | 1 |
| Chen, CH; Chien, RN; Hsieh, SY; Hu, TH; Hung, CH; Lin, CL; Lin, CY; Lu, SN; Sheen, IS; Tung, SY | 1 |
| Hinds, A; Pearlman, B; Perrys, M | 1 |
| Choi, DH; Han, KM; Hwang, SB; Lim, YS; Luong, TTD; Mai, HN; Nguyen, HC; Nguyen, LP; Park, C; Park, EM | 1 |
| Amador, J; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Rajender Reddy, K; Reau, N; Reeve, BB; Sarkar, S; Serper, M; Sterling, RK; Stewart, PW | 1 |
| Skorokhodova, N; Tsarova, O; Zhyvytsia, D | 1 |
| Borba, HHL; Ferreira, VL; Minowa, E; Pontarolo, R; Rochau, U; Siebert, U; Sroczynski, G; Wiens, A | 1 |
| Koike, K; Tanaka, Y; Tateishi, R | 1 |
| Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E | 1 |
| Aglitti, A; Brancaccio, G; Caroleo, B; Claar, E; Coppola, C; Coppola, N; Cozzolongo, R; Di Costanzo, GG; Federico, A; Fontanella, L; Gatti, P; Gentile, I; Longo, A; Masarone, M; Messina, V; Milella, M; Morisco, F; Persico, M; Pierri, P; Rosato, V; Serviddio, G; Sogari, F; Surace, LA; Termite, AP; Terrenato, I; Tundo, P | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kasuya, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sano, T; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Cooke, G; Fawsitt, CG; Vickerman, P; Welton, NJ | 1 |
| Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J | 1 |
| Baicus, C; Constantinescu, I; Diculescu, M; Dumitru, R; Gavrila, D; Istratescu, D; Manuc, M; Manuc, T; Oproiu, A; Preda, CM; Sandra, I; Tieranu, C; Vasilescu, C; Voiosu, T | 1 |
| Chen, CC; Chen, CH; Chen, DS; Chiu, MC; Fang, YJ; Hsu, SJ; Kao, JH; Kuo, CC; Lee, JY; Yang, TH; Yu, JJ | 1 |
| Bakr, MA; El Maghrabi, HM; Elbasiony, MA; Eldahshan, KF; Elmowafy, AY; Matter, YE; Refaie, AF; Rostaing, L; Saleh, HH; Shiha, GE | 1 |
| Fukuchi, T; Kakizaki, S; Naganuma, A; Namikawa, M; Ohnishi, H; Okamoto, H; Sato, K; Uraoka, T | 1 |
| Albrecht, JK; Barnard, RJ; Brass, CA; Chaudhri, E; Davis, MN; Gordon, SC; Hazuda, DJ; Howe, AY; Howe, JA; Jacobson, IM; Kwo, PY; Lawitz, EJ; McCone, J; Ogert, RA; Pedicone, LD; Pound, D; Qiu, P; Ralston, R; Ravendhran, N; Rossaro, L; Schiff, ER; Vierling, JM | 1 |
| Ceccherini-Silberstein, F; Cento, V; De Luca, F; Di Maio, VC; Landonio, S; Magni, C; Micheli, V; Mirabelli, C; Niero, F; Perno, CF; Rizzardini, G | 1 |
| An, D; Barnard, RJ; Bhanja, S; Gane, EJ; Gress, J; Hwang, P; Lawitz, E; Mobashery, N; Rodriguez-Torres, M; Serfaty, L; Stoehr, A | 1 |
| Bernstein, B; Cohen, DE; Koev, G; Kowdley, KV; Larsen, L; Lawitz, E; Menon, R; Pilot-Matias, T; Podsadecki, T; Poordad, F; Siggelkow, S; Tripathi, R | 1 |
| Barnard, RJ; Chase, R; Curry, S; Frontera, MJ; Graham, DJ; Gupta, S; Howe, AY; Howe, JA; Hughes, E; Lahser, F; McMonagle, P; Silva, MO; Treitel, M | 1 |
| Fried, MW; Jensen, DM | 1 |
| Birnkrant, D; Carter, W; Chen, J; Fleischer, RD; Florian, J; Hammerstrom, TS; Jadhav, PR; Murray, J; Zeng, W | 1 |
| Boonstra, A; de Bruijne, J; de Knegt, RJ; Hotho, DM; Janssen, HL; Reesink, HW; Spaan, M; Treitel, MA | 1 |
| Backus, LI; Belperio, PS; Cheung, RC; Hwang, EW; Mole, LA; Thomas, IC | 1 |
| Bota, S; Neghină, AM; Popescu, A; Şirli, R; Sporea, I; Străin, M | 1 |
| Angus, P; Arasteh, K; Asselah, T; Böcher, WO; Bronowicki, JP; Gane, E; Heim, M; Kukolj, G; Larrey, D; Lohse, AW; Mensa, FJ; Müllhaupt, B; Nehmiz, G; Pol, S; Roberts, S; Schuchmann, M; Stern, JO; Zarski, JP; Zeuzem, S; Zoulim, F | 1 |
| Casey, LC; Lee, WM | 2 |
| Ahmed, F | 1 |
| Pawlotsky, JM | 1 |
| de Jong, YP; Jacobson, IM; Jesudian, AB | 1 |
| Aguilera, V; Berenguer, M; Vinaixa, C | 1 |
| Apica, B; Chen, EY; Czul, F; Dubin, P; Lee, WM; Martin, P; Sclair, SN | 1 |
| Bazin-Karra, D; Blanc, F; Cacoub, P; Cazorla, C; Decaux, O; Karras, A; Lambotte, O; Longuet, M; Musset, L; Pialoux, G; Pol, S; Resche Rigon, M; Saadoun, D; Thibault, V; Vittecoq, D; Ziza, JM | 1 |
| Brass, CA; Bronowicki, JP; Chhatwal, J; El Khoury, AC; Elbasha, EH; Ferrante, SA; Poordad, F | 1 |
| Aguilera, A; Barreiro, P; Benito, JM; Fernández-Montero, JV; Labarga, P; Maida, I; Rallón, NI; Rick, F; Sánchez-Parra, C; Soriano, V | 1 |
| Baĭkova, IE; Gogova, LM; Kisliakov, VA; Nikitin, IG; Volynkina, VM | 1 |
| Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourlière, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Dao, T; de Ledinghen, V; Di Martino, V; Dorival, C; Feray, C; Fontaine, H; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Métivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Serfaty, L; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Dolton, MJ; McLachlan, AJ; Ray, JE | 1 |
| Asch, SM; Chan, K; Clark, JA; Gifford, AL; Groessl, EJ; Hanchate, AD; Ho, SB; Lai, MN; Wong, JB | 1 |
| Alberti, A; Bruno, R; Cabibbo, G; Cammà, C; Capursi, V; Craxì, A; Enea, M; Gasbarrini, A; Petta, S; Ruggeri, M | 1 |
| Albrecht, JK; Bacon, BR; Brass, CA; Bronowicki, JP; Burroughs, MH; Davis, M; Deng, W; Dutko, FJ; Esteban, R; Gordon, SC; Lawitz, EJ; Poordad, F; Rajender Reddy, K; Sniukiene, V; Sulkowski, MS; Yoshida, EM | 1 |
| Wang, FS; Wang, LF; Zeng, QL; Zhang, JY; Zhang, Z | 1 |
| Barnard, RJ; Cheney, CA; Dinubile, MJ; Graham, DJ; Hazuda, DJ; Himmelberger, AL; Hwang, PM; McHale, CM; Mobashery, N; Newhard, W; Nickle, D; Reeves, JD; Rivera, AA; Strizki, J | 1 |
| Naggie, S; Osinusi, A | 1 |
| Cooper, C; Fainboim, H; Greaves, W; Howe, AY; Mak, C; Mallolas, J; Pol, S; Rivero, A; Sklar, P; Slim, J; Sulkowski, M; Thompson, S; Wahl, J; Wenning, L | 1 |
| Biesbroeck, LK; Falsey, RR; Moore, E; Scott, JD; Shinohara, MM; Taraska, C | 1 |
| Taylor, DR | 1 |
| Alshuth, U; Hueppe, D; Mauss, S | 2 |
| Corouge, M; Mallet, V; Pol, S; Sogni, P | 1 |
| Brown, J; Paladino, JA; Turner, SJ | 1 |
| Burroughs, M; Hazuda, DJ; Howe, AY; Venkatraman, S; Wahl, J | 1 |
| Brennan, BJ; Chang, L; Giraudon, M; Kulkarni, R; Morcos, PN; Shulman, N; Smith, PF; Tran, JQ | 1 |
| Ehleben, C; Pearlman, BL | 1 |
| Albrecht, J; Barnard, RJ; Brass, CA; Burroughs, M; Gordon, SC; Hazuda, DJ; Howe, JA; Long, J; Ogert, RA; Poordad, F; Qiu, P; Ralston, R; Ryan, D; Sniukiene, V; Strizki, J; Tong, X; Vuocolo, S; Zeuzem, S | 1 |
| Klinker, H; Mauss, S | 1 |
| Everson, GT; Reddy, KR | 1 |
| Urbánek, P | 1 |
| Afdhal, NH; Albrecht, JK; Alves, K; Bacon, BR; Balart, L; Brass, CA; Brown, RS; Burroughs, MH; Calleja, JL; Craxi, A; Deng, W; Dutko, FJ; Flamm, SL; Hézode, C; Koury, KJ; Kowdley, KV; Lawitz, E; Lee, SS; Morgan, TR; Nelson, DR; Nyberg, L; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Sulkowski, MS; Wahl, J; Wedemeyer, H; Zeuzem, S | 1 |
| Asselah, T; Böcher, WO; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Kukolj, G; Lohse, AW; Mensa, FJ; Müllhaupt, B; Roberts, SK; Schuchmann, M; Soriano, V; Stern, JO; Vinisko, R; Zeuzem, S | 1 |
| Kuboki, M; Nishiguchi, S; Omata, M; Sakai, Y; Sakamoto, W; Steinmann, G; Tsuda, Y; Tsunematsu, S; Urano, Y | 1 |
| Bublak, R | 1 |
| Blázquez-Pérez, A; Mar, J; San Miguel, R | 1 |
| Carrier, P; Essig, M; Loustaud-Ratti, V; Vong, C | 1 |
| Bianic, F; Cure, S; Curtis, S; Dusheiko, G; Gavart, S; Lee, S | 1 |
| Boucher, CA; Broekman, MM; Brouwer, JT; Burger, DM; de Knegt, RJ; Drenth, JP; Hoepelman, AI; Lamers, MH; Reesink, HW; van Hoek, B | 1 |
| Akiyama, MJ; Chan, SM; Hong, LK; Huddleston, L; Piotrowski, JI; Roytman, MM; Trujillo, R; Tsai, NC | 1 |
| Galle, PR; Knapstein, J; Zimmermann, T | 1 |
| Pol, S | 1 |
| Bichoupan, K; Dieterich, DT; Shankar, H | 1 |
| Bañares, R; Fernández-Yunquera, A; Rincón, D; Salcedo, M | 1 |
| Back, D; Else, L | 1 |
| Hézode, C | 3 |
| Agarwal, K; Barnabas, A | 1 |
| Carvalho-Filho, RJ; Narciso-Schiavon, JL; Schiavon, LL | 1 |
| Barthe, Y; Bronowicki, JP; Carrat, F; Fontaine, H; Hezode, C | 2 |
| Albrecht, JK; Bacon, B; Balart, L; Bourliere, M; Brass, CA; Bronowicki, JP; Bruno, S; Burroughs, M; Davis, MN; Felizarta, F; Helmond, FA; Kwo, P; Manns, MP; McCone, J; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Schiff, E; Shiffman, ML; Sings, HL; Sulkowski, MS; Vierling, JM | 1 |
| Aghemo, A; Bitetto, D; Bruno, R; Caraceni, P; Ciancio, A; Coco, B; Marzioni, M; Petta, S; Rendina, M; Valenti, L | 1 |
| Barnard, RJ; Bhanja, S; Bourque, M; DiNubile, MJ; Gane, EJ; Hwang, PM; Lawitz, E; Mobashery, N; Rodriguez-Torres, M; Serfaty, L; Stoehr, A; Strizki, J; Zhou, A | 1 |
| Ehleben, CM; Pearlman, BL | 1 |
| Galle, PR; Grambihler, A; Kittner, JM; Koch, S; Schattenberg, JM; Schuchmann, M; Thieringer, F; Weinmann, A; Weiss, NM; Wiltink, J; Zimmermann, T | 1 |
| Calle Serrano, B; Cornberg, M; Maasoumy, B; Manns, MP; Markova, AA; Port, K; Sollik, L; Wedemeyer, H | 1 |
| Gordon, SC; Martins, EB; Yee, LJ | 1 |
| Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ | 1 |
| Lim, TR; Mutimer, DJ; Tan, BH | 1 |
| Antinori, S; Cattaneo, D; Falvella, FS; Gervasoni, C; Magni, C; Milazzo, L; Peri, AM; Vidale, S | 1 |
| Berger, KL; Böcher, WO; Cartier, M; Datsenko, Y; Kukolj, G; Marquis, M; Massariol, MJ; Scherer, J; Steinmann, G; Stern, JO; Triki, I | 1 |
| El Kamary, SS; Kapelusznik, L; Majid, A; McAninch, J; Morgan, DJ; Talwani, R; Zhan, M | 1 |
| Jiang, S; Lawson, KA; Park, C | 1 |
| Ilyas, JA; Vierling, JM | 2 |
| Alberti, A; Colombo, M; Craxì, A; Rizzetto, M | 1 |
| Fontana, RJ; Tischer, S | 1 |
| Brennan, BJ; Gane, EJ; Kulkarni, R; Larrey, DG; Le Pogam, S; Morcos, PN; Nájera, I; Petric, R; Rouzier, R; Shulman, NS; Smith, P; Tran, JQ; Wiercinska-Drapalo, A; Yetzer, ES; Zhang, Y | 1 |
| Courville, P; Duval-Modeste, AB; Goria, O; Joly, P; Leblanc, C; Massy, N; Riachi, G; Samain, A | 1 |
| Laufer, NL; Rockstroh, JK | 1 |
| Girón-Gonzalez, JA; Lopez-Cortes, LF; Pineda, JA; Rivero, A; Rivero-Juarez, A | 1 |
| Beste, LA; Green, PK; Ioannou, GN | 2 |
| Albrecht, J; Brass, C; Bronowicki, JP; Colvard, LY; Davis, M; Deng, W; Flamm, S; Galati, J; Gordon, SC; Helmond, FA; Howe, AY; Jacobson, I; Lawitz, E; Luketic, V; Marcellin, P; McCone, J; Muir, AJ; Pedicone, LD; Poordad, F; Treitel, M; Vierling, JM; Wahl, J; Yoshida, EM | 1 |
| Benhamou, Y; Shiffman, ML | 1 |
| Houlihan, D; McCormick, A; Schmidt-Martin, D | 1 |
| D'Offizi, G; Fazio, S; Giaffreda, A; Lionetti, R; Montalbano, M; Pucillo, LP; Tempestilli, M | 1 |
| Cybula, M; Szemraj, J | 1 |
| Bernstein, B; Cohen, DE; Everson, GT; Foster, GR; Khatri, A; Kowdley, KV; Kwo, P; Larsen, L; Lawitz, E; Liossis, G; Nelson, DR; Pilot-Matias, T; Podsadecki, T; Poordad, F; Sulkowski, MS; Xie, W; Zeuzem, S | 1 |
| Abraham, GM; Gammal, RS; Spooner, LM | 1 |
| Geier, A | 1 |
| Gil-Gómez, I; Lorente-Fernández, L; Marrero-Álvarez, P; Monte-Boquet, E; Poveda-Andrés, JL | 1 |
| Carrion, AF; Gutierrez, J; Martin, P | 1 |
| Florian, J; Mishra, P; Murray, J | 1 |
| Booth, CL; Bridge, SH; Dusheiko, G; Garcia-Diaz, A; Haque, T; Irish, D; Jacobs, M; Labbett, W; Macartney, MJ; McCormick, AL; Rosenberg, W; Smith, C; Tanwar, S; Trembling, P; Velazquez, C | 1 |
| El-Serag, HB; Kanwal, F | 1 |
| Amiri, M; Bailly, F; Funingana, G; Gonçalves, F; Hartig-Lavie, K; Maynard, M; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
| Cotler, SJ; Dahari, H | 1 |
| Shiffman, ML | 1 |
| Chung, RT; deLemos, AS | 1 |
| Haines, K; Li, L; Najera, I; Tong, X | 1 |
| Canva, V; Deltenre, P; Deuffic-Burban, S; Dhumeaux, D; Larrey, D; Mallet, V; Mathurin, P; Obach, D; Pageaux, GP; Pol, S; Roudot-Thoraval, F; Schwarzinger, M; Yazdanpanah, Y | 1 |
| Catalli, L; Chua, J; Manos, MM; Monto, A; Murphy, RC; Pauly, MP; Saxena, V; Shvachko, VA; Terrault, NA; Wayne, E; Yee, HS | 1 |
| Sogni, P | 1 |
| Arama, V; Brisc, C; Caruntu, F; Gheorghe, L; Goldis, A; Iacob, S; Motoc, A; Preotescu, L; Rednic, N; Rugina, S; Simionov, I; Stefan, I | 1 |
| Bruno, R; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Gasbarrini, A; Macaluso, FS; Petta, S; Plaia, A | 1 |
| Druyts, E; Mills, EJ; Thorlund, K | 1 |
| Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourliere, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Chazouilleres, O; Dao, T; De Ledinghen, V; Di Martino, V; Dorival, C; Fontaine, H; Fontanges, T; Gournay, J; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Metivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Portal, I; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Baykal, T; Bernstein, B; Bourlière, M; DaSilva-Tillmann, B; Desmond, P; Di Bisceglie, AM; Hassanein, T; Jacobson, IM; Jensen, DM; Larsen, L; Marinho, RT; Pilot-Matias, T; Podsadecki, T; Poordad, F; Sulkowski, MS; Tam, E; Varunok, P; Wedemeyer, H; Xiong, J; Zeuzem, S | 1 |
| Aguilar, H; Bernstein, B; Coakley, E; Crawford, D; DaSilva-Tillmann, B; Feld, JJ; Kowdley, KV; Larsen, L; Nelson, DR; Pilot-Matias, T; Podsadecki, T; Sigal, S; Weiland, O; Xiong, J | 1 |
| Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M | 1 |
| Agarwal, K; Berg, T; Bernstein, B; Campbell, AL; Collins, CA; Da Silva-Tillmann, B; Forns, X; Hezode, C; Kowdley, KV; Lovell, SS; Podsadecki, T; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H; Yoshida, EM; Zeuzem, S | 1 |
| Angelillo, IF; Coppola, N; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Pavri, TM; Reddy, KR; Sinese, L; Wirjosemito, A | 1 |
| Dybowska, D; Halota, W; Kozielewicz, D | 2 |
| Bacon, BR; Bronowicki, JP; Bruno, S; Deng, W; DiNubile, MJ; Dutko, FJ; Esteban, R; Flamm, SL; Helmond, FA; Koury, KJ; Kwo, PY; Manns, MP; Pedicone, LD; Poordad, F; Vierling, JM; Wahl, J; Zeuzem, S | 1 |
| Agarwal, K; Austin, A; Barclay, ST; Brown, A; Dillon, JF; Dundas, P; Dusheiko, GM; Foster, GR; Fox, R; Hayes, PC; Leen, C; Miller, MH; Millson, C; Ryder, SD; Tait, J; Ustianowski, A | 1 |
| Gimeno-Ballester, V; Mar, J; San Miguel, R | 1 |
| Ghany, MG; Liang, TJ | 1 |
| Baruch, Y; Bernstein, D; Bhandari, BR; Box, TD; Caruntu, FA; Chulanov, V; Cohen, D; Cooper, C; Enayati, P; Ferenci, P; Gervain, J; Green, S; Hassanein, T; Janczewska, E; King, M; Lalezari, J; Luo, Y; Marinho, RT; Moreno, C; Nyberg, A; Planas, R; Podsadecki, T; Reddy, KR; Rizzardini, G; Sepe, T; Tam, E; Tsai, N; Xie, W; Younes, Z | 1 |
| Aichelburg, MC; Boesecke, C; Lang, G; Mandorfer, M; Niederecker, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R; Trauner, M | 1 |
| Berg, T; Buggisch, P; Buslau, A; Hinrichsen, H; Maasoumy, B; Sarrazin, C; Schiefke, I; Wedemeyer, H; Wiegand, J | 1 |
| Degen, O; Eißing, F; Hennigs, A; Hertling, S; Hüfner, A; Jordan, S; Lohse, AW; Lüth, S; Röder, C; Schmiedel, S; Schulze zur Wiesch, J; Sterneck, M; van Lunzen, J; Wehmeyer, MH | 1 |
| Böcher, WO; Hennecke, N; Kayser, A; Kukolj, G; Lohmann, V; Martin, B; Neumann-Haefelin, C; Thimme, R | 1 |
| Bernstein, B; Chevaliez, S; Cloherty, G; Cohen, D; Herman, C; Pawlotsky, JM; Sarrazin, C; Wedemeyer, H | 1 |
| Boldrini, B; Caini, P; Fabbrizzi, A; Fognani, E; Gragnani, L; Laffi, G; Monti, M; Piluso, A; Ranieri, J; Triboli, E; Urraro, T; Zignego, AL | 1 |
| Agarwal, K; Barnabas, A; Orrin, E; Walsh, SA | 1 |
| Belli, LS; Ciaccio, A; Cortesi, PA; De Salvia, S; Lim, JK; Mantovani, LG; Okolicsanyi, S; Rota, M; Strazzabosco, M; Vinci, M | 1 |
| Aherfi, S; Borentain, P; Botta-Fridlund, D; Bregigeon, S; Brouqui, P; Colson, P; Dhiver, C; Gérolami, R; Mokhtari, S; Moreau, J; Motte, A; Poizot-Martin, I; Portal, I; Ravaux, I; Ruiz, JM; Solas, C; Stein, A; Tamalet, C | 1 |
| Ball, JK; Bartenschlager, R; Brown, RJ; Irving, WL; McClure, CP; Pietschmann, T; Rupp, D; Steinmann, E; Than, LM; Titman, A | 1 |
| Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z | 1 |
| Bruno, R; Bruno, S; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Gasbarrini, A; Macaluso, FS; Petta, S; Plaia, A | 1 |
| Devine, S; Kattan, M; Muir, A; Thompson, A | 1 |
| Manos, MM; Murphy, RC; Pauly, MP; Price, JC; Shvachko, VA | 1 |
| Berdeaux, G; Bianic, F; Cure, S; de Knegt, RJ; Lamotte, M; van Agthoven, M; van der Kolk, A; Vellopoulou, A | 1 |
| Dan, YY; Elbasha, EH; Ferrante, SA; Hsu, TY | 1 |
| Hayashi, N; Izumi, N; Mobashery, N | 1 |
| Climente-Martí, M; Gómez-Álvarez, S; Guglieri-López, B; Ventura-Cerdá, JM | 1 |
| Andreone, P; Conti, F; Vitale, G | 1 |
| Aguilera, P; Laguno, M; To-Figueras, J | 1 |
| Fang, L; Hussaini, A; Kleha, JF; Theodore, D; Wire, MB | 1 |
| Backus, LI; Belperio, PS | 1 |
| Blanchard, E; Samaras, K; Vickers, CR | 1 |
| Aichelburg, MC; Grabmeier-Pfistershammer, K; Lang, G; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Alam, I; Argo, CK; Fried, MW; Gordon, SC; Lim, JK; Maliakkal, B; Muir, AJ; Nelson, DR; Pearlman, B; Peter, J; Ramani, A; Reddy, KR; Stewart, TG; Vainorius, M | 1 |
| Bruggmann, P; Fehr, J; Künzler-Heule, P; Nicca, D; Rasi, M; Saxer, S; Schmid, P; Semela, D | 1 |
| Berak, H; Eng, S; Feld, JJ; Foster, GR; Hooper, GJ; Jablkowski, M; Jacobson, IM; Jensen, DM; Kulkarni, R; Le Pogam, S; Lim, CY; Nájera, I; Navarro, MT; Perez-Gomez, HR; Pol, S; Scalori, A; Shahdad, S; Shulman, NS; Tam, E; Tavel, JA; Vierling, JM; Yetzer, ES; Yoshida, EM | 1 |
| Badri, P; Bennett, M; Campbell, A; Hu, Y; Kapoor, M; Lawitz, E; Pilot-Matias, T; Poordad, F; Rodrigues, L; Rodriguez-Torres, M; Sullivan, G; Vilchez, RA | 1 |
| Bock, JA; Fairley, KJ; Inverso, NA; Maeng, DD; Pitcavage, JM; Smith, RE; Williams, MS | 1 |
| Ferreira, AO; Marinho, RT | 1 |
| Almeida, PR; Mattos, AA; Tovo, CV | 1 |
| Böcher, W; Buti, M; Buynak, RJ; Dufour, JF; Gallivan, JP; Mantry, P; Mensa, FJ; Soriano, V; Stern, JO; Taunk, J; Vinisko, R; Zeuzem, S | 1 |
| Boehme, AK; Chen, EY; Dubin, PH; Lee, WM; Martin, P; Rico, R; Sclair, SN | 1 |
| Chayama, K; Hayes, CN | 1 |
| Arenas, J; Babudieri, S; Bollani, S; Bruno, S; Calleja, JL; Calvaruso, V; Caremani, M; Ceccherini Silberstein, F; Chemello, L; Ciancio, A; Colletta, C; Craxì, A; Crespo, J; Forns, X; Gea, F; Larrubia, JR; Magni, C; Maisonneuve, P; Mangia, A; Marenco, S; Moretti, A; Pascasio, JM; Perez-Alvarez, R; Piovesan, S; Zignego, AL | 1 |
| Brennan, B; Canini, L; Chatterjee, A; Guedj, J; Lemenuel-Diot, A; Perelson, AS; Smith, PF | 1 |
| Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Watcha, D | 1 |
| Baroni, GS; Bertino, G; Brancaccio, G; Brindicci, G; Carretta, V; Cenderello, G; Ciancio, A; Cuccorese, G; Forte, P; Mangia, A; Marignani, M; Minerva, N; Mottola, L; Orlandini, A; Piazzolla, V; Picciotto, A; Pirisi, M; Ripoli, M; Zignego, AL; Zuin, M | 1 |
| Stirnimann, G | 1 |
| Agarwal, K; Cohen, D; Podsadecki, T; Poordad, F; Xie, W; Younes, Z | 1 |
| Bory, F; Broquetas, T; Cabrero, B; Cañete, N; Carrión, JA; Coll, S; García-Retortillo, M; Giménez, MD; González-Colominas, E; Knobel, H; Pellicer, R; Retamero, A; Salas, E; Solà, R | 1 |
| Badri, P; Brown, R; Burton, JR; Coakley, E; Forns, X; Gordon, F; Kwo, PY; Levitsky, J; Mantry, PS; Pilot-Matias, T; Setze, C; Te, HS; Terrault, NA; Vargas, HE; Vilchez, RA; Xie, W | 1 |
| Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D | 1 |
| Cornberg, M; Höner zu Siederdissen, C | 1 |
| Berg, T; Hamdi, N; Herrmann, E; Lange, C; Müller, T; Perner, D; Sarrazin, C; Susser, S; Zeuzem, S | 1 |
| Brochot, E; Capron, D; Castelain, S; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E | 1 |
| Asch, SM; Barnett, PG; Dally, SK; Gidwani, R; Goldhaber-Fiebert, JD; Lo, J; Owens, DK | 1 |
| Alves, K; Barnard, R; Howe, AY; Howe, J; Long, J; Nickle, D; Thompson, S; Wahl, J | 1 |
| Bernabucci, V; Cammà, C; Cerami, C; Ciancio, A; Critelli, R; Karampatou, A; Petta, S; Rizzetto, M; Sagnelli, C; Strona, S; Todesca, P; Turco, L; Villa, E | 1 |
| Angus, P; Asselah, T; Böcher, W; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Manns, M; Mensa, FJ; Müllhaupt, B; Roberts, S; Sabo, JP; Schuchmann, M; Soriano, V; Stern, JO; Stickel, F; Voss, F; Zeuzem, S | 1 |
| Butt, AA; Freiberg, MS; Justice, AC; Lo Re, V; Shaikh, OS; Sherman, KE; Yan, P | 1 |
| Bernstein, B; Chevaliez, S; Cloherty, G; Cohen, DE; Herman, C; Pawlotsky, JM; Sarrazin, C; Wedemeyer, H | 1 |
| Bennis, Y; Bodeau, S; Brochot, E; Capron, D; Duverlie, G; Nguyen-Khac, E; Solas, C | 1 |
| Andreoni, M; Angelico, M; Antonucci, FP; Aragri, M; Babudieri, S; Ceccherini-Silberstein, F; Cento, V; De Leonardis, F; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gasbarrini, A; Landonio, S; Lenci, I; Magni, CF; Mancon, A; Manunta, A; Micheli, V; Mura, MS; Nicolini, LA; Nosotti, L; Parruti, G; Pellicelli, A; Perno, CF; Rizzardini, G; Sarrecchia, C; Siciliano, M; Taliani, G; Tontodonati, M; Vecchiet, J | 1 |
| Abel, L; Albert, ML; Barthe, Y; Bronowicki, JP; Carrat, F; Casrouge, A; Dorival, C; Fontaine, H; Fontanet, A; Gayat, E; Hézode, C; Lagaye, S; Mallet, V; Mottez, E; Pol, S; Sultanik, P; Theodorou, I | 1 |
| Agarwal, K; Asselah, T; Bourlière, M; Calinas, F; Crespo, J; Datsenko, Y; Dufour, JF; Ferenci, P; Forton, D; Foster, GR; Garcia, M; Kukolj, G; Maevskaya, M; Morano, LE; Moreno, C; Nishiguchi, S; Omata, M; Ouzan, D; Quinson, AM; Sarrazin, C; Scherer, J; Schuchmann, M; Stern, JO; Zehnter, E; Zeuzem, S | 1 |
| Andreone, P; Gamal, N; Vitale, G | 1 |
| Abraham, GM; Akushevich, L; Di Bisceglie, AM; El-Genaidi, H; Fenkel, JM; Fried, MW; Kuo, A; Mah'moud, MA; Nelson, DR; Rustgi, VK; Sterling, RK; Stewart, PW; Stewart, TG; Sulkowski, MS | 1 |
| Alric, L; Bailly, F; Bourlière, M; Bronowicki, JP; Carrat, F; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Loustaud-Ratti, V; Métivier, S; Pradat, P; Samuel, D; Serfaty, L; Virlogeux, V; Zarski, JP; Zoulim, F | 1 |
| Descamps, V; Fiszenson-Albala, F | 1 |
| Badri, P; Chayama, K; Kumada, H; Kurosaki, M; Notsumata, K; Pilot-Matias, T; Rodrigues, L; Sato, K; Setze, C; Vilchez, RA | 1 |
| Awni, WM; Badri, PS; Coakley, EP; Dutta, S; Hu, B; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Wang, T; Zha, J | 1 |
| Arends, JE; Dabis, F; Fontaine, H; Gilbert, C; Lacombe, K; Loko, MA; Miailhes, P; Puoti, M; Rockstroh, JK; Rosenthal, E; Salmon, D; Sogni, P; Winnock, M; Wittkop, L | 1 |
| Boglione, L; Cardellino, CS; Cariti, G; D'Avolio, A; De Nicolò, A; Di Perri, G; Ghisetti, V; Ruggiero, T | 1 |
| Gale, SE; Klibanov, OM; Santevecchi, B | 1 |
| Arastéh, K; Bhagani, S; Dieterich, D; Guardiola, JM; Ingiliz, P; Jain, MK; Kort, J; Laguno, M; Manero, M; Nelson, M; Rockstroh, JK; Soriano, V; Stern, JO; Tural, C; Vinisko, R | 1 |
| Hedrick, KT; Just, SM; Kahn, DR | 1 |
| Abdelrahman, T; Aitken, C; Gunson, RN; MacLean, AR; Shepherd, SJ; Thomson, EC | 1 |
| Butterton, JR; Feng, HP; Hulskotte, EG; Khalilieh, S; Wenning, LA | 1 |
| Kowdley, KV; Minaei, AA | 1 |
| Behrer, CR; Kalsekar, A; Le, TK; Macaulay, D; Sorg, RA; Wei, J; Wu, EQ; Yuan, Y | 1 |
| Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D | 1 |
| Akiyama, MJ; Cheung, R; Ha, NB; Li, J; Nguyen, MH; Piotrowski, JI; Roytman, MM; Tsai, N; Vo, KP; Vu, VD; Vutien, P; Wantuck, J | 1 |
| Asselah, T; Berenguer, M; Fleischer-Stepniewska, K; Hall, C; Hassanein, T; Hézode, C; Marcellin, P; Mobashery, N; Pilot-Matias, T; Pol, S; Reddy, KR; Redman, R; Schnell, G; Vilchez, RA | 1 |
| Aguilar, H; Cohen, DE; Felizarta, F; Galen, E; King, M; Kowdley, KV; Lalezari, J; McGovern, B; Polepally, AR; Rustgi, V; Sullivan, JG; Varunok, P | 1 |
| Brayer, SW; Reddy, KR | 1 |
| Anderson, M; Caro, L; Cerra, M; Du, L; Manns, MP; Nachbar, RB; Panorchan, P; Potthoff, A; Talal, AH; Wagner, J; Wright, DH | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Peck-Radosavljevic, M | 1 |
| Beck, R; Berg, CP; Egetemeyr, DP; Franz, C; Lauer, UM; Malek, NP; Werner, CR | 1 |
| Feld, JJ; Sharma, SA | 1 |
| Albillos, A; Hernández-Guerra, M; Luis Calleja, J; Molina, E; Planas, R; Romero-Gómez, M; Turnes, J | 1 |
| Bhagani, S; Collado, A; de Los Santos-Gil, I; Delgado, M; Fehr, J; Haberl, A; López-Cortés, LF; Lutz, T; Mandorfer, M; Márquez, M; Mauss, S; Munteanu, DI; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S; Stoeckle, M | 1 |
| Abravanel, F; Alain, S; André-Garnier, E; Baazia, Y; Besse, B; Bouvet, D; Bouvier-Alias, M; Brochot, E; Caporossi, A; David-Tchouda, S; Duverlie, G; Fleury, H; Gaudy-Graffin, C; Gouriou, S; Gozlan, J; Guivarch, M; Haïm-Boukobza, S; Halfon, P; Hantz, S; Henquell, C; Lada, O; Lagathu, G; Larrat, S; LeGuillou-Guillemette, H; Mackiewicz, V; Margier, J; Maylin, S; Mirand, A; Mohamed, S; Morand, P; Mourez, T; Pawlotsky, JM; Pivert, A; Plantier, JC; Pronier, C; Ramière, C; Roque-Afonso, AM; Scholtes, C; Schvoerer, E; Thibault, V; Trimoulet, P; Vallet, S; Velay, A | 1 |
| Ho, S; Mehnert, A; Pacou, M; Pettré, S; Pisini, M; Taieb, V; Ustianowski, A; Van Sanden, S | 1 |
| Bárcena, R; Berenguer, M; Buti, M; Calleja, JL; Crespo, J; Fernández, I; González, O; López, J; Pérez, F | 1 |
| Afdhal, NH; Rourke, M; Sethi, N; Sethi, S; Tapper, EB; Vong, A | 1 |
| Feld, JJ; Shah, H; Sheehan, K; Sockalingam, S | 1 |
| Athanasakis, K; Ferrante, SA; Hill, M; Kyriopoulos, II; Kyriopoulos, J; Petrakis, I; Retsa, MP | 1 |
| Halász, T; Horváth, G; Hunyady, B; Makara, M | 1 |
| Deeks, ED | 1 |
| Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ | 1 |
| Ampuero, J; Andrade, RJ; Buti, M; Cabezas, J; Calleja, JL; Crespo, J; Del Campo, JA; Fernández, I; Forns, X; Lens, S; Millán, R; Rojas, L; Romero-Gómez, M | 1 |
| Kmietowicz, Z | 1 |
| Alberti, A; De Franceschi, L; Dissegna, D; Donato, F; Fattovich, G; Ieluzzi, D; Iolascon, A; Lupo, F; Matté, A; Piovesan, S; Raffetti, E; Russo, R; Siciliano, A; Toniutto, P; Turrini, F; Zuliani, V | 1 |
| Kalsekar, A; Le, TK; Macaulay, D; Sorg, RA; Wei, J; Wu, EQ; Yuan, Y | 1 |
| Arain, A; Bastens, B; Bourgeois, S; Bruckers, L; Buntinx, F; d'Heygere, F; de Galocsy, C; Deltenre, P; Francque, S; George, C; Henrion, J; Janssens, F; Laleman, W; Mathei, C; Moreno, C; Nevens, F; Robaeys, G; Van Overbeke, L; Van Vlierberghe, H; Verrando, R | 1 |
| Ambrosioni, J; Aouri, M; Böni, J; Cavassini, M; Decosterd, L; Fehr, J; Furrer, H; Günthard, HF; Haubitz, S; Kovari, H; Ledergerber, B; Metzner, KJ; Rauch, A; Schaerer, V; Schmid, P; Stoeckle, M | 1 |
| Burroughs, M; Chayama, K; Ikeda, K; Karino, Y; Kioka, K; Kumada, H; Matsuzaki, Y; Patwardhan, M; Pilot-Matias, T; Redman, R; Rodrigues, L; Sato, K; Setze, C; Suzuki, F; Toyoda, H; Vilchez, RA | 1 |
| Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
| Fraenkel, L; Garcia-Tsao, G; Lim, J; Monto, A; Reyna, V | 1 |
| Akarca, US; Hall, C; Hézode, C; Lawitz, E; Makara, M; Mobashery, N; Morillas, RM; Pilot-Matias, T; Preotescu, LL; Redman, R; Thuluvath, PJ; Varunok, P; Vilchez, RA | 1 |
| Berger, KL; Kukolj, G; Quinson, AM; Ranga, M; Scherer, J; Sha, N; Stern, JO | 1 |
| Recker, K | 1 |
| Allam, S; Boursier, J; Bronowicki, JP; Canva, V; De Lédinghen, V; Ducancelle, A; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Moal, V; Poynard, T; Veillon, P; Vergniol, J; Zoulim, F | 1 |
| Gissel, C; Götz, G; Mahlich, J; Repp, H | 1 |
| Altus, R; Colman, A; Dan, YY; Fragomelli, V; Galhenage, S; Guan, R; Jones, T; Lee, YM; Leembruggen, N; Lim, SG; Luman, W; Mason, S; Mollison, L; Morales, B; Nazareth, S; Pham, T; Piratvisuth, T; Sendall, C; Sukeepaisarnjaroen, W; Sutedja, D; Tan, SS; Tanwandee, T; Teo, EK; Than, YM; Totten, L; Wigg, A | 1 |
| Berenguer, M; Everson, G; Ferenci, P; Forns, X; Fried, MW; Lopez-Talavera, JC; Lovell, S; Pedrosa, M; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H | 1 |
| Birch, C; Clausen, MR; Gaardbo, JC; Gerstoft, J; Hartling, HJ; Hove, M; Nielsen, SD; Trøseid, M; Ullum, H | 1 |
| Beyer, J; Collins, C; Dekhtyar, T; Hall, C; Krishnan, P; Lu, L; Pilot-Matias, T; Reisch, T; Schnell, G; Tripathi, R; Vilchez, RA | 1 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 1 |
| Arends, JE; Brinkman, K; Hoepelman, AI; Kortmann, W; Posthouwer, D; Reiss, P; Richter, C; Schinkel, J; Smit, C; van Assen, S; van der Ende, M; van der Meer, JT; van der Valk, M | 1 |
| Arama, V; Campbell, A; Caruntu, FA; Conway, B; Curescu, M; Dalgard, O; Dore, GJ; Fuster, F; Ghesquiere, W; Greenbloom, S; Janczewska, E; Kapoor, M; Knysz, B; Liu, X; Liu, Y; Luo, Y; Mazur, W; Motoc, A; Podsadecki, T; Sasadeusz, J; Shaw, D; Skoien, R; Soza, A; Streinu-Cercel, A; Sullivan, D; Tornai, I | 1 |
| Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M | 1 |
| Cockerham-Colas, L; Heo, M; Litwin, AH; Reynoso, S; Roose, RJ; Soloway, IJ; Tenore, C | 1 |
| Cattaneo, D; Charbe, N; Clementi, E; Gervasoni, C; Resnati, C; Sollima, S | 1 |
| Cheng, PN; Hsu, SJ; Huang, CF; Lai, HC; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, CW; Su, WW; Tsai, WL; Tseng, KC; Wang, CH; Yang, CC; Yu, ML | 1 |
| Carrascosa, R; Llamas-Velasco, M; Montes-Torres, A; Sánchez-Pérez, J | 1 |
| Burger, DM; Buti, M; de Kanter, CT; DeMasi, R; Dofferhoff, AS; Drenth, JP; Ouwerkerk-Mahadevan, S; Witek, J; Zeuzem, S | 1 |
| Hayashi, N; Howe, AY; Kumada, H; Ludmerer, SW; Mobashery, N; Nakamuta, M; Takase, A; Takehara, T | 1 |
| Bronowicki, JP; Hézode, C | 1 |
| Abel, S; Coakley, E; Cohen, DE; Davis, JW; Dumas, EO; Dutta, S; Podsadecki, T; Waring, JF | 1 |
| Babudieri, S; Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Falasca, K; Maggi, P; Magni, C; Martinelli, C; Menzaghi, B; Nicolini, LA; Parruti, G; Quirino, T; Ricci, E; Salomoni, E; Vichi, F | 1 |
| Amber, KT | 1 |
| Bernstein, DE; Bourgeois, S; Elkhashab, M; Feld, JJ; Fu, B; Horsmans, Y; Howieson, K; Larsen, L; Moreno, C; Pangerl, A; Polepally, AR; Poordad, F; Reindollar, RW; Shulman, NS; Tam, E; Trinh, R; Younes, Z | 1 |
| Baldanti, F; Barbarini, G; Bruno, R; Fiorina, L; Gulminetti, R; Landini, V; Mariani, B; Maserati, R; Novati, S; Paolucci, S | 1 |
| Alves, K; Badri, PS; Ding, B; Dutta, S; Menon, RM; Redman, R; Rodrigues, L; Uchiyama, N; Zha, J | 1 |
| Dybowska, D; Karwowska, K; Kozielewicz, D; Wietlicka-Piszcz, M | 1 |
| Brunda, M; Chu, T; Elston, R; Gane, EJ; George, J; Glavini, K; Hammond, JM; Jensen, DM; Le Pogam, S; Nájera, I; Passe, S; Piekarska, A; Rodriguez, I; Zeuzem, S | 1 |
| Canini, L; Chatterjee, A; Guedj, J; Lemenuel-Diot, A; Perelson, AS; Smith, PF | 1 |
| Asselah, T; Bourlière, M; Dufour, JF; Ferenci, P; Forton, D; Foster, GR; García-Samaniego, J; Maevskaya, M; Mantry, P; Oliveira, C; Quinson, AM; Sha, N; Stern, JO; Warner, N; Wright, D; Wright, M; Yoshida, EM | 1 |
| Awni, WM; Cohen, D; Ding, B; Dutta, S; King, JR; Menon, RM; Podsadecki, TJ | 1 |
| Lim, A; Smith, MA | 1 |
| Busuttil, RW; Cheng, EY; Holt, CD; Saab, S | 1 |
| Ahmed, II; Anand, N; Ilyas, F; Singh, H | 1 |
| Husa, P | 1 |
| Abel, L; About, F; Albert, ML; Bronowicki, JP; Cagnot, C; Carrat, F; Cobat, A; Duffy, D; Fontaine, H; Hézode, C; Larrey, D; Marcellin, P; Niay, J; Oudot-Mellakh, T; Pedergnana, V; Pol, S; Rabiéga, P; Sultanik, P; Theodorou, I; Zoulim, F | 1 |
| Andolina, A; Bagaglio, S; Galli, A; Hasson, H; Lazzarin, A; Merli, M; Messina, E; Morsica, G; Uberti-Foppa, C | 1 |
| Awni, WM; Chiu, YL; Dutta, S; Klein, CE; Menon, RM; Podsadecki, TJ | 1 |
| Adeyi, O; Chen, L; Cotler, SJ; Deneke, MG; Duarte-Rojo, A; Feld, JJ; Fischer, SE; Malespin, M; McGilvray, ID; Selzner, N; Zita, D | 1 |
| Asatryan, A; Box, TD; Campbell, A; Freilich, BL; Kort, J; Lawitz, EJ; Lin, CW; Liu, W; Lovell, S; Ng, TI; O'Riordan, WD; Overcash, JS; Yao, B | 1 |
| Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
| Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H | 1 |
| Forns, X; Hézode, C; Le Pogam, S; Lee, SS; Nájera, I; Scalori, A; Thommes, JA; Voulgari, A; Wedemeyer, H | 1 |
| Asatryan, A; Fu, B; Jackson, DF; Kort, J; Landis, CS; Lin, CW; Ng, TI; Poordad, F; Yao, B | 1 |
| Banerjee, D; Reddy, KR | 1 |
| Hashimoto, T; Ishii, N; Ohzono, A | 1 |
| Takehara, T | 1 |
| Fabbrizzi, A; Fognani, E; Genovesi, A; Giubilei, L; Gragnani, L; Monti, M; Petraccia, L; Piluso, A; Ranieri, J; Stasi, C; Urraro, T; Zignego, AL | 1 |
| Arends, JE; Burger, DM; Friederich, P; Koek, GH; Lieveld, FI; Siersema, PD; van Erpecum, KJ; van Meer, S; van Nieuwkerk, KM; van Vlerken, LG | 1 |
| Abdel-Hameed, EA; Anwar, N; Hetta, HF; Ji, H; Rouster, SD; Shata, MT; Sherman, KE; Ulm, A | 1 |
| Chiu, YL; Ding, B; Dumas, EO; Khatri, A; King, JR; Menon, RM; Podsadecki, TJ; Polepally, AR; Shuster, DL | 1 |
| Butt, AA; Chung, RT; Shaikh, OS; Sherman, KE; Yan, P | 1 |
| Chayama, K; Fujimoto, G; Howe, AY; Karino, Y; Kumada, H; Ludmerer, SW; Mobashery, N; Mochida, S; Nakamura, K; Suzuki, F | 1 |
| Horn, M; Horvath, A; Jurse, P; Leber, B; Lemesch, S; Posch, A; Schmerböck, B; Spindelboeck, W; Stadlbauer, V; Stauber, RE; Stiegler, P; Streit, A; Tawdrous, M; Wuensch, G; Zettel, G | 1 |
| An, D; Brainard, DM; Di Bisceglie, AM; Dvory-Sobol, H; Freilich, B; Glass, S; Hassman, D; Hill, J; Kim, S; Kirby, BJ; Krefetz, D; Lawitz, E; Marbury, T; Rodriguez-Torres, M; Smith, W; Stamm, LM; Taylor, JG; Yang, JC | 1 |
| Benali, S; Bourliere, M; Camus, C; Castellani, P; Chiche, L; Gonzalez, D; Halfon, P; Khiri, H; Mohamed, S; Olive, D; Oules, V; Penaranda, G; Sayada, C | 1 |
| Brennan, BJ; Hill, G; Kao, JH; Le Pogam, S; Lee, Y; Li, H; Najera, I; Sheen, IS; Tanwandee, T; Thommes, JA; Thongsawat, S; Tung, SY; Wu, JJ; Zhou, J | 1 |
| Imaizumi, N; Kashiwagi, T; Kashiwamura, S; Kishida, Y; Tanimura, H | 1 |
| Batskikh, SN; Chulanov, VP; Karandashova, IV; Neverov, AD | 1 |
| Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML | 1 |
| Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A | 1 |
| Flisiak, R; Parfieniuk-Kowerda, A; Łucejko, M | 1 |
| Gopalakrishnan, S; Khatri, A; Menon, R; Mensing, S; Redman, R; Zha, J | 1 |
| Angus, P; Böcher, W; Buti, M; Buynak, RJ; Dufour, JF; Kadus, W; Mantry, P; Mensa, FJ; Pockros, PJ; Soriano, V; Stern, JO; Vinisko, R; Wright, D; Zeuzem, S | 1 |
| Barrail-Tran, A; Bellissant, E; Bourlière, M; Cotte, L; Fournier, I; Garraffo, R; Kheloufi, F; Lacarelle, B; Molina, JM; Poizot-Martin, I; Quaranta, S; Renault, A; Solas, C | 1 |
| Awni, W; Dutta, S; Khatri, A; Menon, R; Mensing, S; Podsadecki, T | 1 |
| Badri, PS; Eckert, D; Menon, RM; Mensing, S; Polepally, AR | 1 |
| Filipovic, I; Johnson, SJ; Misurski, D; Parisé, H; Samp, JC; Virabhak, S | 1 |
| Bartenschlager, R; Beggel, B; Heger, E; Kaiser, R; Kalaghatgi, P; Knops, E; Lengauer, T; Neumann-Fraune, M; Obermeier, M; Rupp, D; Sierra, S; Sikorski, AM; Timm, J; Walker, A; Walter, H | 1 |
| Barnard, R; Blinco, J; Chopra, A; Gaudieri, S; Hazuda, D; Jabara, CB; James, I; Lemon, SM; Mallal, S; Watson, MW | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Gopalakrishnan, SM; Khatri, A; Menon, RM; Mensing, S; Polepally, AR | 1 |
| Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A | 1 |
| Igarashi, A; Johnson, S; Mitchell, D; Samp, JC; Virabhak, S; Yamazaki, K; Yasui, K; Yuen, C | 1 |
| Goncales, ES; Goncales, FL; Lazarini, MS; Mendes, LC; Miotto, N; Pedro, MN; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Cariani, E; Pecoraro, V; Trenti, T; Villa, E | 1 |
| Khoury, J; Saadi, T | 1 |
| Awni, WM; Dutta, S; Khatri, A; Marbury, TC; Menon, RM; Preston, RA; Rodrigues, L; Wang, H | 1 |
| Akhan, S; Ayaz, C; Aygen, B; Aynioglu, A; Demirturk, N; Ersoz, G; Inan, D; Karakecili, F; Keten, D; Koculu, S; Korkmaz, F; Kose, Ş; Mistik, R; Sargin Altunok, E; Sayan, M; Tekin Koruk, S; Tuna, N; Ural, O; Yazici, S; Yildirmak, T; Yildiz, O | 1 |
| Keating, GM | 1 |
| Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C | 1 |
| Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z | 1 |
| Beavers, K; Bernstein, D; Brainard, DM; Chung, RT; Davis, M; Dvory-Sobol, H; Etzkorn, K; Everson, G; Gane, EJ; Gordon, SC; Khalid, O; Kowdley, KV; Kwo, PY; Lu, S; McHutchison, JG; Nguyen, MH; Poulos, JE; Pound, D; Rodriguez-Torres, M; Stamm, LM; Stedman, CA; Tong, M; Tsai, N; Yang, JC | 1 |
| Berger, KL; Côté-Martin, A; Kukolj, G; Marquis, M; Mensa, FJ; Nelson, DR; Sarrazin, C; Scherer, J; Sha, N; Stern, JO; Vinisko, R | 1 |
| Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Zhao, W | 1 |
| Srinivas, NR | 1 |
| Alric, L; Anty, R; Beaulieux, F; Botta-Fridlund, D; Bouix, C; Canva, V; Carrieri, MP; Conti, F; D'Alteroche, L; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fontaine, H; Lebray, P; Leroy, V; Maynard, M; Métivier, S; Pageaux, GP; Paul, C; Petrov-Sanchez, V; Pradat, P; Roche, B; Roque-Afonso, AM; Samuel, D; Vilotitch, A; Wellems, C | 1 |
| Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D | 1 |
| Hiensch, RJ; Oberg, CL; Poor, HD | 1 |
| Heger, E; Inden, S; Kaiser, R; Kalaghatgi, P; Knops, E; Neumann-Fraune, M; Schübel, N; Sierra, S | 1 |
| De Weggheleire, A; Dorlo, TP; Francque, S; Lynen, L; Meessen, B; Newton, PN; Pouget, C; Ravinetto, R; Sokkab, A; Tabernero, P | 1 |
| Ashby, CR; Jankovich, RD; Jodlowski, TZ; Puglisi, GM; Smith, SM | 1 |
| But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF | 1 |
| Huang, CF; Jang, TY; Lu, PL; Yu, ML | 1 |
| Alqahtani, S; Calinas, F; Crawford, D; Dumas, EO; Feld, JJ; Ferenci, P; Gane, E; Gschwantler, M; Isakov, V; Jacobson, IM; King, M; Ozaras, R; Sulkowski, M; Wyles, D | 1 |
| Andreone, P; Magalotti, D; Martino, E; Masetti, M; Scuteri, A; Zoli, M | 1 |
| Bai, X; Calleja, JL; Forns, X; Garcia-Samaniego, J; Kaste, R; Manns, M; Sarrazin, C; Stern, JO; Wu, J | 1 |
| Horiguchi, N; Hosonuma, K; Kakizaki, S; Kobayashi, T; Kusano, M; Ohnishi, H; Okamoto, H; Sato, K; Takakusagi, S; Yamada, M; Yamazaki, Y | 1 |
| Friedel, H; Fröhlich, H; Thönnes, S | 1 |
| Cornberg, M; Deterding, K; Fischer, N; Grundhoff, A; Manns, MP; Schlevogt, B; Steinmann, E; Todt, D; Wedemeyer, H | 1 |
| Asatryan, A; Bernstein, DE; Felizarta, F; Flamm, SL; Fried, MW; Gordon, SC; Kort, J; Landis, CS; Lin, CW; Liu, R; Lovell, SS; Mensa, FJ; Ng, TI; Poordad, F; Reindollar, RW; Sulkowski, MS | 1 |
| Aichelburg, MC; Bucsics, T; Ferenci, P; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Alvarez, M; Butt, ZA; Chong, M; Cook, D; Darvishian, M; Islam, N; Janjua, NZ; Krajden, M; Ramji, A; Samji, H; Tyndall, M; Wong, J; Yoshida, EM | 1 |
| Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J | 1 |
| Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y | 1 |
| Badri, PS; Dutta, S; Menon, RM; Shuster, DL | 1 |
| Awni, WM; Dutta, S; Khatri, A; Menon, RM; Polepally, AR | 1 |
| D'Offizi, G; Gasbarrini, A; Gianserra, L; Lionetti, R; Pasquazzi, C; Pompili, M; Ponziani, FR; Siciliano, M | 1 |
| Kronenberger, B; Zeuzem, S | 3 |
| Inoue, K; Watanabe, T; Yamada, M; Yoshiba, S | 1 |
| Antinori, S; Milazzo, L | 1 |
| Albrecht, JK; Anderson, FH; Brass, CA; Chaudhri, E; Davis, MN; Galati, JS; Gordon, SC; Jacobson, IM; Koury, K; Kwo, PY; Lawitz, EJ; McCone, J; Pedicone, LD; Pound, D; Ravendhran, N; Rossaro, L; Rubin, R; Schiff, ER; Vierling, JM | 1 |
| Chen, KX; Njoroge, FG | 1 |
| Benhamou, Y; Bradford, B; Couzigou, P; Forestier, N; Guyader, D; Larrey, D; Marcellin, P; Moucari, R; Seiwert, S; Vidaud, M; Voitot, H; Zeuzem, S | 1 |
| Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, EA; Janssen, HL; Li, J; Molenkamp, R; Reesink, HW; Schinkel, J; Tong, X; Treitel, MA; van Lier, JJ; van Vliet, AA; Weegink, CJ | 1 |
| Thomas, DL | 1 |
| Angus, PW; Baher, L; Berrey, MM; Bradford, W; Chu, T; Elston, R; Gane, EJ; Ipe, D; Laughlin, M; Lopatin, U; Morcos, PN; Najera, I; Ritchie, B; Roberts, SK; Shulman, NS; Smith, PF; Stedman, CA | 1 |
| Carroll, SS; Davies, ME; Graham, D; Handt, L; Hazuda, D; Koeplinger, K; Liverton, N; Ludmerer, SW; MacCoss, M; Olsen, DB; Zhang, NR | 1 |
| Blatt, L; Bradford, W; Forestier, N; Guyader, D; Larrey, D; Marcellin, P; Patat, A; Porter, S; Rouzier, R; Seiwert, SD; Smith, P; Zeuzem, S | 1 |
| Lange, CM; Sarrazin, C; Zeuzem, S | 1 |
| Asselah, T; Marcellin, P | 2 |
| Halfon, P; Locarnini, S | 1 |
| Ciesek, S; Manns, MP | 1 |
| Chang, L; Gane, EJ; Horban, A; Nájera, I; Rouzier, R; Sampeur, P; Shulman, NS; Smith, P; Stedman, C; Tran, JQ; Wiercinska-Drapalo, A; Zhang, Y | 1 |
| Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Bronowicki, JP; Bruno, S; DiNubile, MJ; Goodman, ZD; Jacobson, IM; Manns, MP; McCone, J; Poordad, F; Reddy, KR; Sniukiene, V; Sulkowski, MS | 1 |
| Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Burroughs, M; Esteban, R; Goodman, ZD; Gordon, SC; Lawitz, E; Marcellin, P; Poordad, F; Sings, HL; Vierling, JM; Zeuzem, S | 1 |
| Jensen, DM | 1 |
| Hofmann, WP; Zeuzem, S | 1 |
| Enserink, M | 1 |
| Bradford, W; Kossen, K; Lim, SR; Lin, JH; Pan, L; Schaefer, CJ; Seiwert, SD; Smith, PF | 1 |
| Hunyady, B | 1 |
| Barreiro, P; Fernandez-Montero, JV; Labarga, P; Martin-Carbonero, L; Poveda, E; Soriano, V; Vispo, E | 1 |
| Rice, C | 1 |
| Traynor, K | 2 |
| Alcorn, MC; Dieterich, DT; Rabkin, JG; Weiss, JJ | 1 |
| Hsu, CS; Kao, JH | 1 |
| Cabrera, R; Draganov, PV; Limaye, AR | 1 |
| Corouge, M; Pol, S | 1 |
| Khungar, V; Poordad, F | 1 |
| Chung, TL; Herrmann, E; Hofmann, WP; Karey, U; Lötsch, J; Mihm, U; Osbahr, C; Sarrazin, C; Susser, S; Welsch, C; Zeuzem, S | 1 |
| Belliveau, PP; Foote, BS; Spooner, LM | 1 |
| Manns, M | 1 |
| Back, D; Dieterich, D; Peters, M; Rockstroh, J; Sherman, KE; Soriano, V; Sulkowski, M | 1 |
| Jazwinski, AB; Muir, AJ | 1 |
| Dore, GJ; Matthews, GV; Rockstroh, J | 1 |
| Ghany, MG; Nelson, DR; Seeff, LB; Strader, DB; Thomas, DL | 1 |
| Angus, P; Arasteh, K; Asselah, T; Boecher, WO; Bronowicki, JP; Gane, E; Haefner, C; Heim, M; Kukolj, G; Larrey, D; Lohse, A; Müllhaupt, B; Nehmiz, G; Pol, S; Roberts, S; Schuchmann, M; Stern, JO; Zarski, JP; Zeuzem, S; Zoulim, F | 1 |
| Stiefelhagen, P | 1 |
| Back, D; Seden, K | 1 |
| Bousquet, C; Dansereau, N; Dô, F; Kukolj, G; Lagacé, L; Llinas-Brunet, M; Marquis, M; Massariol, MJ; Maurice, R; Spickler, C; Thibeault, D; Triki, I; White, PW; Zhao, S | 1 |
| Lok, AS; Sharma, P | 1 |
| Rademacher, K; Schafer, JA; Tungol, A | 1 |
| Spooner, LM | 1 |
| Arfsten, A; Bradford, W; Herrmann, E; Hong, J; Hooi, L; Kossen, K; Lange, C; Lim, SR; Nájera, I; Nicholas, JB; Qin, X; Sarrazin, C; Seiwert, SD; Smith, P; Susser, S; Zeuzem, S | 1 |
| Harrington, PR; Naeger, LK; Zeng, W | 2 |
| Kwo, PY; Maddur, H | 1 |
| Battyáni, Z; Hunyady, B; Kovács, B | 1 |
| Muir, AJ | 1 |
| Buti, M; Homs, M | 1 |
| Iqbal, M; McCormick, PA | 1 |
| Williams, SC | 1 |
| Ferenci, P; Reddy, KR | 1 |
| Gambarin-Gelwan, M; Jacobson, IM | 1 |
| Bartlett, JG; Peters, MG; Pham, PA; Sherman, KE; Sulkowski, MS; Thomas, DL | 1 |
| Calle Serrano, B; Cornberg, M; Manns, MP; Markova, AA | 1 |
| Forestier, N; Zeuzem, S | 1 |
| Kwo, PY | 2 |
| Bacon, BR; Khalid, O | 1 |
| Esteban, R; Shiffman, ML | 1 |
| Adhoute, X; Benali, S; Bourlière, M; Castellani, P; Khaloun, A; Oules, V; Portal, I; Wartelle-Bladou, C | 1 |
| Roche, B; Samuel, D | 1 |
| Sulkowski, MS | 1 |
| Mangia, A; Mottola, L | 1 |
| Kumar, CK; Sarin, SK | 1 |
| El Kassas, M; El Raziky, M; Esmat, G; Gamil, ME; Hassany, M | 1 |
| Fried, MW; McGowan, CE | 1 |
| Berg, T; Cornberg, M; Dollinger, M; Ferenci, P; Hinrichsen, H; Klinker, H; Kraus, M; Manns, M; Mauss, S; Peck-Radosavljevic, M; Sarrazin, C; Schmidt, H; Spengler, U; Wedemeyer, H; Wirth, S; Zeuzem, S | 1 |
| Barreiro, P; Labarga, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| Angus, PW; Chu, TW; Elston, R; Gane, EJ; Germer, S; Iglesias, VA; Ipe, D; Kulkarni, R; Lopatin, U; Lu, XY; Ritchie, B; Roberts, SK; Shulman, NS; Smith, PF; Stedman, C | 1 |
| Fontaine, H; Pol, S | 1 |
| Agarwal, K; Austin, A; Brown, A; Dillon, JF; Foster, GR; Fox, R; Fraser, A; Hayes, PC; Leen, C; Mills, PR; Mutimer, DJ; Ramachandran, P; Ryder, SD | 1 |
| Hézode, C; Pawlotsky, JM; Sarrazin, C; Zeuzem, S | 1 |
| Anderson, PL; Burton, JR; Everson, GT; Kiser, JJ | 1 |
| Crespo, G; Lens, S | 1 |
| Dusheiko, GM; Tanwar, S; Trembling, PM | 1 |
| Afdhal, NH; Dusheiko, GM; Forns, X; Jacobson, IM; Jensen, DM; Pawlotsky, JM; Poordad, F; Schulz, J | 1 |
| Domínguez Muñoz, E; Fernández Castroagudín, J; Molina Pérez, E | 1 |
| Giordano, C | 1 |
| Francque, S; Ho, E; Michielsen, P | 1 |
| Fomsgaard, A; Gerstoft, J | 1 |
| Beard, MR; Locarnini, SA; Thompson, AJ | 1 |
| Bronte, F; Bruno, R; Cammà, C; Capursi, V; Cicchetti, A; Colombo, GL; Craxì, A; Di Marco, V; Enea, M; Gasbarrini, A; Petta, S | 1 |
| Barnard, RJ; Caro, L; Gane, E; Hwang, PM; Lee, AW; Manns, MP; Marcellin, P; Rodriguez-Torres, M; Stoehr, A; Wiedmann, RT; Yeh, CT | 1 |
| Saxena, V; Terrault, N | 1 |
| Jacobson, I; Jesudian, A; Welsch, C; Zeuzem, S | 1 |
| Ford, JA; Greanya, E; Partovi, N; Wilby, KJ; Yoshida, EM | 1 |
| Ingiliz, P; Rockstroh, JK | 1 |
| McHutchison, JG; Thompson, AJ | 1 |
| Erdmann, J | 1 |
| Chang, MF; Lim, J; Monto, A; Morgan, TR; Pocha, C; Ross, D; Yee, HS | 1 |
| Chevaliez, S; Pawlotsky, JM; Rodriguez, C | 1 |
| Barritt, AS; Fried, MW | 1 |
| Thompson, AJ | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Bruguera, M; Esteban, R; Forns, X; Planas, R; Quer, JC; Solà, R; Vergara, M | 1 |
| Amur, S; Pacanowski, M; Zineh, I | 1 |
| Amur, S; Ayala, R; Florian, J; Harrington, P; Jadhav, PR; Mishra, P; Murray, J; O'Rear, J; Pacanowski, M; Robertson, S; Singer, M; Soon, G; Zeng, W | 1 |
| Benhamou, Y; Boyer, N; Carenco, C; Guyader, D; Larrey, D; Marcellin, P; Pageaux, GP; Rouzier, R | 1 |
| Albrecht, JK; Boparai, N; Brass, CA; Bronowicki, JP; Bruno, S; Burroughs, MH; Deng, W; DiNubile, MJ; Esteban, R; Gottesdiener, KM; Jacobson, IM; Marcellin, P; Pedicone, LD; Poordad, F; Sulkowski, MS; Zeuzem, S | 1 |
| Pearlman, BL | 1 |
| Aghemo, A; Colombo, M; Degasperi, E | 1 |
| Fox, AN; Jacobson, IM | 1 |
| Mayer, KH; Swan, T; Taylor, LE | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Crosbie, O; Fanning, LJ; Hegarty, K; Kenny-Walsh, E; Levis, J; O'Sullivan, K | 1 |
| Burton, MJ; McGuire, BM; Passarella, MJ | 1 |
| Ali, S; Chhabra, M; Chin, DJ; Ilnicka, M; Kang, H; Klumpp, K; Kosaka, A; Le Pogam, S; Nájera, I; Shulman, NS; Smith, P; Yan, JM | 1 |
| Bourgeois, S; Colle, I; De Maeght, S; Deltenre, P; Delwaide, J; Francque, S; Laleman, W; Moreno, C; Mulkay, JP; Orlent, H; Reynaert, H; Stärkel, P | 1 |
| Bourlière, M; Bronowicki, JP; Delasalle, P; Leroy, V; Pageaux, GP; Pariente, A; Pol, S; Serfaty, L; Zoulim, F | 1 |
| Antonini, TM; Barau, C; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Noël, C; Roche, B; Roque-Afonso, AM; Samuel, D; Taburet, AM | 1 |
| Grammatikos, G; Vermehren, J; Zeuzem, S | 1 |
| Boesecke, C; Rockstroh, JK | 1 |
| Dusheiko, G; Wedemeyer, H | 1 |
| Rockstroh, JK; Schwarze-Zander, C | 1 |
| Chang, MH; Fung, HB; Gordon, LA | 1 |
| Bianic, F; Cure, S; Diels, J; Gavart, S; Jones, E | 1 |
| Ouzan, D | 1 |
| Chandy, GM; Conjeevaram, H; Jothimani, D | 1 |
| Albrecht, JK; Bacon, BR; Barnard, RO; Bourlière, M; Brass, CA; Burroughs, MH; Flamm, SL; Goteti, V; Hezode, C; Howe, JA; Jacobson, I; Lawitz, E; Niederau, C; Pedicone, LD; Poordad, F; Sherman, M; Sings, HL; Vierling, JM | 1 |
| Afdhal, NH; Albrecht, JK; Brass, CA; Bronowicki, JP; Burroughs, MH; Harrison, SA; Jacobson, IM; Koury, KJ; Manns, MP; Pedicone, LD; Poordad, F; Rajender Reddy, K; Sings, HL; Sniukiene, V; Sulkowski, MS | 1 |
| Flemming, JA; Terrault, NA | 1 |
| Deltenre, P; Moreno, C | 1 |
| Barreiro, P; Benito, JM; Fernández-Montero, JV; Labarga, P; Poveda, E; Rallon, N; Sánchez, C; Soriano, V; Vispo, E | 1 |
| Asselah, T | 2 |
| Cooper, C; Druyts, E; El Khoury, AC; Lester, R; Mills, EJ; Thorlund, K; Yaya, S | 1 |
| Carlson, A; Gregorich, Z; Striker, R | 1 |
| Burton, JR; Everson, GT | 1 |
| de Knegt, RJ; Janssen, HL; Pan, Q; Peppelenbosch, MP | 1 |
| Barrantes-González, M; González-Colominas, E; Salas, E; Solà, R | 1 |
| Gellad, ZF; Muir, AJ; Reed, SD | 1 |
| Gane, E | 1 |
| Jacobson, IM; Marks, KM | 1 |
| Rodríguez-Torres, M | 1 |
| Boonstra, A; Janssen, HL; Spaan, M | 1 |
| Buti, M; Esteban, R | 1 |
| Sarrazin, C; Vermehren, J | 1 |
| Jacob, S; Lam, JT | 1 |
| Garnock-Jones, KP | 1 |
| Maasoumy, B; Manns, MP | 1 |
| Abu-Mouch, S; Baruch, Y; Ben-Ari, Z; Bruck, R; Kaspa, RT; Lurei, Y; Oren, R; Safadi, R; Shibolet, O; Shouval, D; Zuckerman, E | 1 |
| Chhatwal, J; El Khoury, AC; Elbasha, EH; Ferrante, SA; Laires, PA | 1 |
| Asselah, T; Bessone, F; Böcher, WO; Datsenko, Y; Fainboim, H; Ferenci, P; Heo, J; Kukolj, G; Lalezari, J; Leggett, B; Mauss, S; Nehmiz, G; Scherer, J; Steinmann, GG; Stern, JO; Sulkowski, MS | 1 |
| Harrington, PR; Lontok, E; Mani, N; Miller, V | 1 |
| Comee, MK; Malloy, M; Silva, M; Sitole, M; Spooner, L | 1 |
| Heil, EL; Hynicka, LM | 1 |
| Bes, M; Cubero, M; Esteban, JI; Esteban, R; Guardia, J; Otero, T; Quer, J; Sauleda, S | 1 |
180 review(s) available for proline and Chronic Hepatitis C
| Article | Year |
|---|---|
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Design; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Microbial Sensitivity Tests; Molecular Conformation; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants | 2020 |
Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Non-Randomized Controlled Trials as Topic; Proline; Pyrrolidines; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins | 2020 |
Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzofurans; Carbamates; Drug Therapy, Combination; Global Health; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Proline; Pyrrolidines; Sofosbuvir; Sulfonamides; Uracil; Valine; World Health Organization | 2020 |
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: case report and literature review.
Topics: Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Republic of Korea; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature.
Topics: Aged; Aminoisobutyric Acids; Antibodies, Monoclonal; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Multiple Myeloma; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2017 |
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2017 |
Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2017 |
Glecaprevir/Pibrentasvir: First Global Approval.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Approval; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2017 |
Citius, Altius, Fortius: The New Paradigm in the Treatment of Chronic Hepatitis C Disease.
Topics: Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Mutation; Proline; Sulfonamides; Valine | 2018 |
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine | 2017 |
Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carrier Proteins; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Drug Resistance, Viral; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Costs; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides | 2018 |
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2018 |
Danoprevir: First Global Approval.
Topics: Antiviral Agents; China; Cyclopropanes; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Managing hepatitis C therapy failures and chronic kidney disease.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Cardiovascular Diseases; Cyclopropanes; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sulfonamides; Treatment Failure | 2018 |
Expert opinion on the management of renal manifestations of chronic HCV infection.
Topics: 2-Naphthylamine; Amides; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Disease Management; Drug Therapy, Combination; Expert Testimony; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Practice Guidelines as Topic; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Risk Factors; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Treatment of hepatitis C virus genotype 4 in the DAA era.
Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
[Advances in combination therapy of ombitasvir and dasabuvir for chronic hepatitis C virus genotype 1 infection].
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Proline; Sulfonamides; United States; Uracil; Valine | 2018 |
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Fibrosis; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Sulfonamides; Treatment Outcome | 2019 |
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
Topics: 2-Naphthylamine; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Denmark; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Prognosis; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Uracil; Valine | 2019 |
Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Administration Routes; Drug Therapy, Combination; Female; Gastrostomy; Hepatitis C, Chronic; Humans; Intubation, Gastrointestinal; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Odds Ratio; Oligopeptides; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Hepatitis C virus therapy update 2013.
Topics: Antiviral Agents; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors | 2013 |
NS5A inhibitors in the treatment of hepatitis C.
Topics: Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Proline; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2013 |
Emerging therapeutic targets for hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin | 2013 |
[Progress in hepatitis C treatment].
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2013 |
[Boceprevir: new possibilities for antiviral treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Proline; Serine Proteinase Inhibitors | 2013 |
Sofosbuvir and ABT-450: terminator of hepatitis C virus?
Topics: Animals; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Interferons; Interleukins; Lactams, Macrocyclic; Macrocyclic Compounds; Patient Selection; Phenotype; Polymorphism, Genetic; Precision Medicine; Proline; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2013 |
Evolution of cell culture systems for HCV.
Topics: Antiviral Agents; Cell Culture Techniques; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Virus Cultivation; Virus Replication | 2013 |
Protease inhibitors for hepatitis C: economic implications.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality of Life; Recombinant Proteins; Ribavirin | 2013 |
Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.
Topics: Animals; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Proline; Protease Inhibitors; Treatment Outcome | 2013 |
Drug-drug interactions in the treatment of HCV among people who inject drugs.
Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Substance Abuse, Intravenous | 2013 |
[Treatment of chronic hepatitis C virus infection at the beginning of a new era].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Polyethylene Glycols; Proline | 2013 |
The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Ribavirin | 2013 |
Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Drug Interactions; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Monitoring, Physiologic; Oligopeptides; Patient Selection; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic | 2013 |
The importance of drug-drug interactions in the DAA era.
Topics: Antiviral Agents; Contraindications; Cytochrome P-450 CYP3A; Databases, Pharmaceutical; Drug Interactions; Hepatitis C, Chronic; Humans; Internet; Oligopeptides; Proline | 2013 |
Management of anaemia and other treatment complications.
Topics: Anemia; Antiviral Agents; Contraindications; Drug Eruptions; Drug Therapy, Combination; Dysgeusia; Hemorrhoids; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Patient Selection; Platelet Count; Polyethylene Glycols; Proline; Pruritus Ani; Ribavirin; Serum Albumin | 2013 |
Treatment of chronic hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Drug Interactions; End Stage Liver Disease; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Proline; Ribavirin; Secondary Prevention | 2013 |
Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin | 2014 |
Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline | 2014 |
Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.
Topics: Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline | 2014 |
An overview of emerging therapies for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Metabolic Networks and Pathways; Oligopeptides; Pharmacogenetics; Proline; Therapies, Investigational; Viral Hepatitis Vaccines; Virus Physiological Phenomena | 2014 |
Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.
Topics: Administration, Oral; Anti-Bacterial Agents; Antiviral Agents; Calcineurin Inhibitors; Chemical and Drug Induced Liver Injury; Drug Interactions; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Transplantation; Oligopeptides; Proline; Risk Factors; Tacrolimus; TOR Serine-Threonine Kinases | 2014 |
Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.
Topics: Aminoisobutyric Acids; Antiviral Agents; Biological Availability; Clinical Trials as Topic; Coinfection; Drug Administration Schedule; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Leucine; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Thiazoles; Virus Replication | 2014 |
HCV F1/F2 patients: treat now or continue to wait.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Treatment Outcome; Uridine Monophosphate | 2014 |
[The role of hepcidin and polymorphisms in the regulatory region of the IL-28B gene in HCV infections].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Hepcidins; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polymorphism, Genetic; Prognosis; Proline; Protease Inhibitors; Regulatory Sequences, Nucleic Acid; Ribavirin; Treatment Outcome | 2013 |
[Hepatitis C update: what has changed? What can we expect in the near future?].
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Approval; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Drugs, Investigational; Germany; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Prognosis; Proline; Protease Inhibitors | 2013 |
New antiviral agents for the treatment of hepatitis C: ABT-450.
Topics: Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins | 2014 |
Hepatitis C virus therapy in the direct acting antiviral era.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Sofosbuvir; Thiazoles; Uridine Monophosphate | 2014 |
Hepatitis C treatment: an incipient therapeutic revolution.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; Sofosbuvir; Uridine Monophosphate | 2014 |
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.
Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors.
Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Poland; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin | 2013 |
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
Topics: Adult; Aged; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2014 |
Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature.
Topics: Cost-Benefit Analysis; Drug Labeling; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Quality-Adjusted Life Years | 2014 |
Treating hepatitis C in the elderly: the future is near?
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2014 |
Emerging treatments for chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline | 2015 |
Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Proline; Ribavirin; Valine; Viral Nonstructural Proteins | 2014 |
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Which therapeutic option for hepatitis C virus genotype 1?
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Oligopeptides; Proline; Randomized Controlled Trials as Topic; Simeprevir; Sofosbuvir; Viral Load | 2015 |
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine | 2015 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Tablets; Uracil; Valine | 2015 |
Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.
Topics: Animals; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2015 |
ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Uracil; Valine | 2015 |
Management of post transplant hepatitis C in the direct antiviral agents era.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2015 |
Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy.
Topics: Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Ritonavir; Sulfonamides | 2015 |
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2015 |
Management of HCV in cirrhosis-a rapidly evolving landscape.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline | 2015 |
[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Liver Cirrhosis; Medication Adherence; Metabolic Syndrome; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Risk Factors | 2014 |
A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials as Topic; Databases, Bibliographic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Viral Load | 2015 |
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Proline; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Management of direct-acting antiviral agent failures.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uracil; Uridine Monophosphate; Valine | 2015 |
Ideal oral combinations to eradicate HCV: The role of ribavirin.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Valine | 2016 |
Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carrier Proteins; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Macrocyclic Compounds; Molecular Targeted Therapy; Proline; Protease Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Nonstructural Proteins | 2015 |
[Possibilities of IFN-free therapy of hepatitis C].
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2016 |
Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.
Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides | 2016 |
Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Pilot Projects; Proline; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Valine | 2017 |
Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Area Under Curve; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Function Tests; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Renal Insufficiency; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Valine | 2016 |
Clinical Pharmacokinetics of Ombitasvir.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Food-Drug Interactions; Hepacivirus; Hepatitis C, Chronic; Humans; Proline; Valine | 2017 |
Clinical Pharmacokinetics of Paritaprevir.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Sulfonamides | 2017 |
Future treatment options for HCV: double, triple, what is the optimal combination?
Topics: Antiviral Agents; Cytidine; DNA-Directed RNA Polymerases; Drug Delivery Systems; Drug Resistance, Viral; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Oligopeptides; Polyethylene Glycols; Prodrugs; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin | 2008 |
[Novel treatment for chronic hepatitis C in near future].
Topics: Drug Delivery Systems; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors | 2009 |
The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
Topics: Animals; Antiviral Agents; Drug Design; Hepacivirus; Hepatitis C, Chronic; Humans; Molecular Structure; Proline; Protease Inhibitors; Structure-Activity Relationship; Viral Nonstructural Proteins | 2010 |
[Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins; Virus Replication | 2011 |
New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Signal Transduction; Standard of Care; Virus Replication | 2011 |
Hepatitis C virus resistance to protease inhibitors.
Topics: Antiviral Agents; Drug Resistance, Viral; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Liver; Models, Molecular; Mutation; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins; Virus Replication | 2011 |
Hepatitis in 2010: the dawn of a new era in HCV therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2011 |
A new standard of care for the treatment of chronic HCV infection.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Oligopeptides; Pharmacogenetics; Proline; Standard of Care; Treatment Outcome; United States | 2011 |
[New therapeutic options in chronic hepatitis C virus infection].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Directly acting antivirals against hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Discovery; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline | 2011 |
New treatments for chronic hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Serine Proteinase Inhibitors; Therapies, Investigational | 2011 |
Emerging therapeutic options in hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Oligopeptides; Proline; Quinolines; Simeprevir; Sulfonamides; Thiazoles; Treatment Outcome; Viral Load; Virus Replication | 2011 |
Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2011 |
An overview of emerging therapies for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Nucleosides; Oligopeptides; Proline; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2011 |
Future of hepatitis C therapy: development of direct-acting antivirals.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Oligopeptides; Proline; Protease Inhibitors; Treatment Outcome | 2011 |
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Oligopeptides; Proline; Protease Inhibitors | 2011 |
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Topics: Adolescent; Adult; Aged; Algorithms; Clinical Trials, Phase III as Topic; Drug Costs; Female; Hepatitis C, Chronic; Humans; Male; Managed Care Programs; Middle Aged; Oligopeptides; Patient Compliance; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; RNA, Viral; Viral Load; Young Adult | 2011 |
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Topics: Affect; Anemia, Hypochromic; Antiviral Agents; Autoimmune Diseases; Autoimmunity; Cardiovascular System; Clinical Trials as Topic; Drug Eruptions; Drug Synergism; Drug Therapy, Combination; Endocrine System Diseases; Eye; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon-alpha; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Respiratory System; Ribavirin; Risk Factors; Thrombocytopenia | 2011 |
Telaprevir for the treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
[New agents for the treatment of hepatitis C].
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Discovery; Drug Eruptions; Drugs, Investigational; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Spain; Viral Nonstructural Proteins | 2012 |
Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.
Topics: Drug Resistance, Viral; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors | 2012 |
Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome | 2012 |
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Withholding Treatment | 2012 |
Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Treatment Failure; Treatment Outcome; Virus Replication; Young Adult | 2012 |
Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indiana; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2012 |
Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Substitution; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Standard of Care; Treatment Failure | 2012 |
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
Topics: Algorithms; Anemia; Antiviral Agents; Clinical Protocols; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Time Factors; Viral Load | 2012 |
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
Topics: Antiviral Agents; Disease Eradication; Drug Administration Schedule; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2012 |
Future treatment of patients with HCV cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2012 |
Hepatitis C virus treatment pre- and post-liver transplantation.
Topics: Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load | 2012 |
Hepatitis C virus-human immunodeficiency virus coinfection.
Topics: Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load | 2012 |
What's new in HCV genotype 2 treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2012 |
Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load | 2012 |
The future for the treatment of genotype 4 chronic hepatitis C.
Topics: Albumins; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Thiazoles; Time Factors; Viral Load; Vitamin D | 2012 |
Barriers to hepatitis C treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Refusal; Viral Load | 2012 |
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors | 2012 |
Treatment failure with new hepatitis C drugs.
Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Phenotype; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure | 2012 |
Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins | 2011 |
Antiviral strategies in hepatitis C virus infection.
Topics: Antiviral Agents; Cyclophilins; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins | 2012 |
Review and management of drug interactions with boceprevir and telaprevir.
Topics: Anti-Retroviral Agents; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Male; Oligopeptides; Proline; Risk Assessment; Treatment Outcome | 2012 |
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; RNA, Viral; Treatment Outcome | 2012 |
Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2012 |
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors; Viremia | 2012 |
Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Liver Neoplasms; North America; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome; Viral Load | 2012 |
Resistance to anti-HCV protease inhibitors.
Topics: Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Molecular; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins; Virus Replication | 2011 |
Hepatitis C therapy update.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Factors | 2012 |
Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin | 2012 |
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Serine Proteinase Inhibitors | 2012 |
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Disease Management; Disease Progression; Drug Interactions; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load | 2012 |
HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.
Topics: Coinfection; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Oligopeptides; Proline; Serine Proteinase Inhibitors | 2012 |
Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
Topics: Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Oligopeptides; Polymorphism, Genetic; Proline; Treatment Outcome | 2012 |
New virologic tools for management of chronic hepatitis B and C.
Topics: Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Point-of-Care Systems; Polyethylene Glycols; Proline; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome | 2012 |
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Topics: Anemia, Hypochromic; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Tract; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; United States | 2012 |
Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials.
Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors; Treatment Outcome | 2013 |
[Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
Topics: Antiviral Agents; Carrier Proteins; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Oligopeptides; Poland; Proline; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.
Topics: Antiviral Agents; Coinfection; Disease Progression; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Incidence; Liver Cirrhosis; Mass Screening; Proline; Risk-Taking; RNA, Viral; Sexual Behavior | 2012 |
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.
Topics: Antiviral Agents; Drug Combinations; France; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors | 2012 |
[Chronic hepatitis C: improved cure rates with new approved medications].
Topics: Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigational; Genotype; Guideline Adherence; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2012 |
Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2012 |
[Boceprevir (Victrelis), oral administration].
Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Proline; Ribavirin | 2012 |
Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.
Topics: Antiviral Agents; Bayes Theorem; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Randomized Controlled Trials as Topic | 2012 |
A new era in the treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2013 |
[Management of chronic hepatitis C in 2012 in Belgium].
Topics: Antiviral Agents; Belgium; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Humans; Models, Biological; Oligopeptides; Proline | 2012 |
Interferon stimulated genes and hepatitis C virus infection.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2012 |
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Boceprevir and treatment of chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors | 2013 |
Management of the transplant recipient with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferons; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Care; Preoperative Care; Proline; Ribavirin; Serine Proteinase Inhibitors | 2013 |
Telaprevir/boceprevir era: from bench to bed and back.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Translational Research, Biomedical; Treatment Outcome | 2012 |
Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
Topics: Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Economic; Oligopeptides; Proline; Treatment Outcome; United States | 2012 |
Future perspectives: towards interferon-free regimens for HCV.
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Treatment Outcome | 2012 |
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Topics: Algorithms; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2012 |
Immunology of hepatitis C virus infections.
Topics: Adaptive Immunity; Antiviral Agents; Dendritic Cells; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Killer Cells, Natural; Liver; Oligopeptides; Proline; T-Lymphocytes | 2012 |
Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2012 |
The role of resistance in HCV treatment.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Microbial Sensitivity Tests; Molecular Targeted Therapy; Mutation; Oligopeptides; Proline; Protease Inhibitors; Ribavirin | 2012 |
Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Proline; Protease Inhibitors | 2012 |
Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.
Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Proline; Randomized Controlled Trials as Topic; Treatment Outcome; Viral Load | 2012 |
Optimal treatment with boceprevir for chronic HCV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins | 2013 |
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2013 |
Anemia management in patients with chronic viral hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Hematinics; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2013 |
179 trial(s) available for proline and Chronic Hepatitis C
| Article | Year |
|---|---|
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Death, Sudden; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Rwanda; Sofosbuvir; Sulfonamides; Treatment Failure | 2022 |
Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; COVID-19; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pandemics; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides | 2022 |
Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Area Under Curve; Benzimidazoles; Biological Availability; Body Weight; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Models, Biological; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Young Adult | 2020 |
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Young Adult | 2020 |
Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.
Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Coinfection; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Raltegravir Potassium; Ritonavir; Sulfonamides; Uracil; Valine | 2020 |
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2020 |
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Biopsy, Fine-Needle; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams, Macrocyclic; Leucine; Liver; Male; Middle Aged; Proline; Sulfonamides; Tissue Distribution; Young Adult | 2020 |
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.
Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Kinetics; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; United States; Uracil; Valine; Viral Load | 2020 |
High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life exp
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2020 |
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Antiviral Agents; Biomarkers; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Immunologic Factors; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Carbamates; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Leucine; Middle Aged; Proline; Pyrrolidines; Ritonavir; Russia; Sulfones; Treatment Outcome; Urea; Valine | 2019 |
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Asia; Benzimidazoles; Case-Control Studies; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Placebos; Prevalence; Proline; Pyrrolidines; Quinoxalines; Respiratory Tract Infections; Safety; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pilot Projects; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response | 2021 |
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Topics: 2-Naphthylamine; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine; Young Adult | 2021 |
Epigenetic scars of CD8
Topics: 2-Naphthylamine; Anilides; Antigens, Viral; Antiviral Agents; CD8-Positive T-Lymphocytes; Chromatin; Cyclopropanes; Epigenesis, Genetic; Hepacivirus; Hepatitis C, Chronic; High Mobility Group Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunologic Memory; Lactams, Macrocyclic; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2021 |
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Predictive Value of Tests; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial).
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Comorbidity; Double-Blind Method; Female; Fluorenes; Health Status; Hepatitis C, Chronic; Humans; Male; Mental Health; Middle Aged; Oligopeptides; Patient Reported Outcome Measures; Polyethylene Glycols; Proline; Quality of Life; Severity of Illness Index; Sex Factors; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Uracil; Viral Load | 2017 |
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Young Adult | 2017 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2016 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2016 |
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2017 |
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uracil; Valine | 2017 |
Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.
Topics: Aged; Antiviral Agents; Brazil; Cross-Sectional Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; RNA, Viral; Treatment Outcome | 2017 |
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Methadone; Middle Aged; Naloxone; Opiate Substitution Treatment; Opioid-Related Disorders; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Surveys and Questionnaires; Young Adult | 2017 |
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Valine | 2018 |
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2018 |
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Topics: Adult; Aged; Alanine Transaminase; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2018 |
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Placebos; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome | 2018 |
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; RNA, Viral; Sulfonamides; Viral Load | 2017 |
IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interleukins; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Recurrence; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2017 |
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoquinolines; Japan; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Viral Nonstructural Proteins | 2018 |
Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome | 2018 |
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2018 |
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome | 2018 |
Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cluster Analysis; Cyclopropanes; Demography; Europe; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Molecular Epidemiology; North America; Phylogeny; Prevalence; Proline; Ritonavir; Sequence Analysis, DNA; Sulfonamides; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2018 |
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Topics: Adult; Aged; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Graft Rejection; Graft Survival; Hepatitis C, Chronic; Humans; Internationality; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver Transplantation; Male; Middle Aged; Prognosis; Proline; Pyrrolidines; Quinoxalines; Risk Assessment; Sulfonamides; Transplant Recipients; Treatment Outcome | 2018 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Republic of Belarus; Ribavirin; Ritonavir; Russia; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2018 |
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2018 |
Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Linear Models; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Asian People; Carbamates; China; Cyclopropanes; Female; Healthy Volunteers; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Republic of Korea; Ritonavir; Sulfonamides; Taiwan; Uracil; Valine | 2019 |
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.
Topics: Antiviral Agents; Clinical Protocols; Decision Making; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin | 2018 |
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2018 |
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sulfonamides; Viral Load | 2018 |
Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
Topics: Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Recurrence; Retreatment; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.
Topics: Adult; Aged; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Drug Combinations; Fatigue; Female; Genotype; Headache; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.
Topics: 2-Naphthylamine; Adult; Aged; Antiviral Agents; Chemokines; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon-alpha; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Sulfonamides; Sustained Virologic Response; Uracil | 2019 |
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Brazil; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
Topics: Aged; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Kidney; Lactams, Macrocyclic; Leucine; Male; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Glucose Intolerance; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Salvage Therapy; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Viremia | 2019 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Severity of Illness Index; Sulfonamides; Sustained Virologic Response | 2019 |
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Liver Diseases; Male; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2019 |
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2019 |
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Pilot Projects; Proline; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult | 2013 |
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins | 2013 |
Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Replicon; RNA, Viral; Viral Load; Viral Nonstructural Proteins | 2013 |
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfones; Treatment Outcome; Urea; Viral Load | 2013 |
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load | 2013 |
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
Topics: Aged; Antiviral Agents; Cohort Studies; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Vasculitis | 2014 |
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2013 |
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2013 |
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Peptide Hydrolases; Polyethylene Glycols; Proline; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viremia; Young Adult | 2013 |
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Renal Insufficiency | 2014 |
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
Topics: Adult; Antiviral Agents; Aryl Hydrocarbon Hydroxylases; Cyclopropanes; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Midazolam; Middle Aged; Proline; Ritonavir; Sulfonamides; Vitamin K; Warfarin; Young Adult | 2013 |
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.
Topics: Antiviral Agents; Contraindications; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Topics: Algorithms; Anemia; Antiviral Agents; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Faldaprevir and deleobuvir for HCV genotype 1 infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Thiazoles; Viral Load | 2013 |
Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Asian People; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Time Factors; Treatment Outcome | 2014 |
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Young Adult | 2014 |
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Placebos; Proline; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Topics: Adult; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Evolution, Molecular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sulfones; Urea; Viral Load; Viral Nonstructural Proteins | 2013 |
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Mutation; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2014 |
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Viral Load | 2014 |
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
Topics: Administration, Oral; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; RNA, Viral; Sulfonamides; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Base Sequence; Cyclopropanes; Deoxycytidine; DNA Replication; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Molecular Sequence Data; Mutation; Phenotype; Proline; RNA, Viral; Sequence Analysis, DNA; Sulfonamides; Viral Nonstructural Proteins | 2014 |
A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prognosis; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2014 |
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Load; Young Adult | 2014 |
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load; Young Adult | 2014 |
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; Sulfonamides; Valine | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Valine | 2014 |
Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.
Topics: Acrylates; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Contraindications; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Virus Replication | 2014 |
HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals.
Topics: 2-Naphthylamine; Antiviral Agents; Biological Assay; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Oligopeptides; Polyethylene Glycols; Proline; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Uracil; Viral Load | 2015 |
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Prognosis; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Singapore; Treatment Outcome; Viral Load | 2015 |
Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.
Topics: Adult; Antiviral Agents; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Young Adult | 2015 |
Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Topics: Adult; Area Under Curve; Benzoates; Calcium; Cross-Over Studies; Diet; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Oligopeptides; Proline; Purpura, Thrombocytopenic; Pyrazoles; Receptors, Thrombopoietin; Serine Proteinase Inhibitors; Young Adult | 2014 |
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2015 |
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Topics: Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2015 |
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2015 |
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; RNA, Viral; Thiazoles; Treatment Outcome | 2015 |
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.
Topics: Antiviral Agents; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Theoretical; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2015 |
An interferon-free antiviral regimen for HCV after liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Mutation; Phenotype; Proline; Recurrence; Treatment Failure | 2015 |
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Logistic Models; Menopause; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
Topics: Acrylates; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Female; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Quinolines; Ribavirin; Thiazoles; Young Adult | 2015 |
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.
Topics: Administration, Oral; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Pilot Projects; Prognosis; Proline; Ribavirin; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2015 |
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Topics: Aged; Antiviral Agents; Area Under Curve; beta 2-Glycoprotein I; Biomarkers; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles | 2015 |
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
Topics: Adolescent; Adult; Age Factors; Aged; Algorithms; Antiviral Agents; Biomarkers; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Young Adult | 2015 |
Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine; Young Adult | 2015 |
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Topics: 2-Naphthylamine; Administration, Oral; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2015 |
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Leucine; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load; Viremia; Young Adult | 2015 |
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2015 |
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Analgesics, Opioid; Anilides; Antiviral Agents; Buprenorphine; Carbamates; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Methadone; Middle Aged; Opioid-Related Disorders; Proline; Retrospective Studies; Ribavirin; Sulfonamides; Uracil; Valine; Young Adult | 2015 |
Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Biopsy; Cyclopropanes; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Liver; Liver Cirrhosis; Male; Middle Aged; Proline; Sulfonamides | 2015 |
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2015 |
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
Topics: Aged; Anilides; Antiviral Agents; Asian People; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Valine | 2015 |
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Carbamates; Carrier Proteins; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Remission Induction; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States; Valine; Viral Nonstructural Proteins | 2015 |
Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Resistance, Viral; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Mutation; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Hypoalbuminemia; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Sulfonamides; Thrombocytopenia; Treatment Outcome; Uracil; Valine; Young Adult | 2015 |
Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Phylogeny; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2015 |
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Sulfonamides; Uracil; Valine | 2016 |
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Japan; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sulfonamides; Treatment Outcome; Young Adult | 2016 |
Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; MicroRNAs; Proline; Sulfonamides; Uracil; Valine; Virus Replication | 2016 |
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2016 |
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Topics: Adult; Antiviral Agents; Australia; Benzothiadiazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; New Zealand; Phenotype; Proline; Quinolones; Remission Induction; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.
Topics: Antiviral Agents; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Biological; Proline; RNA, Viral; Sulfonamides; Viral Load | 2016 |
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Placebos; Proline; Quinolines; Ribavirin; Salvage Therapy; Thiazoles; Treatment Outcome | 2016 |
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.
Topics: Adult; Antiviral Agents; Bilirubin; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; Healthy Volunteers; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Young Adult | 2016 |
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Microbial Sensitivity Tests; Middle Aged; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult | 2015 |
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2016 |
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Topics: Adult; Antibodies, Viral; Antimetabolites; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2016 |
High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; United States | 2016 |
Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring.
Topics: Antiviral Agents; Drug Monitoring; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Ribavirin | 2016 |
Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HLA Antigens; Humans; Immunity, Cellular; Male; Middle Aged; Mutation; Pilot Projects; Proline; Prospective Studies; Protease Inhibitors; Recurrence; RNA, Viral; T-Lymphocytes; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Pharmacokinetics; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2016 |
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Young Adult | 2016 |
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Elastase; Male; Middle Aged; Neutrophils; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome | 2016 |
GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Placebos; Proline; Quinoxalines; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2016 |
Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Young Adult | 2016 |
A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection.
Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-beta; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Sulfonamides | 2016 |
Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Valine | 2016 |
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
Topics: Acrylates; Adult; Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Leucine; Male; Middle Aged; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Quinolines; Ribavirin; RNA, Viral; Sustained Virologic Response; Thiazoles; Time Factors; Treatment Outcome; United States | 2016 |
Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Young Adult | 2016 |
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
Topics: Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Proline; Renal Insufficiency; Ritonavir; Sex Factors; Sulfonamides; Valine; Young Adult | 2017 |
Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Diseases; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Anti-Retroviral Agents; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Interactions; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lactams, Macrocyclic; Lamivudine; Macrocyclic Compounds; Male; Middle Aged; Oxazines; Piperazines; Proline; Pyridones; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Diarrhea; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2016 |
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
Topics: Acrylates; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Prognosis; Proline; Quinolines; Ribavirin; RNA, Viral; Thiazoles; Viral Load; Young Adult | 2016 |
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Leucine; Liver Function Tests; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load; Young Adult | 2017 |
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Load; Viral Nonstructural Proteins | 2010 |
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Proline; Protease Inhibitors; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins | 2010 |
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inpatients; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Outpatients; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ritonavir; RNA, Viral; Sulfones; Urea; Young Adult | 2010 |
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; RNA, Viral; Sulfonamides; Viral Nonstructural Proteins | 2010 |
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Carrier Proteins; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Sulfonamides; Viral Load; Viral Nonstructural Proteins | 2011 |
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Topics: Adult; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Time Factors | 2011 |
Boceprevir for untreated chronic HCV genotype 1 infection.
Topics: Adult; Anemia; Antiviral Agents; Black People; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2011 |
Boceprevir for previously treated chronic HCV genotype 1 infection.
Topics: Anemia; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2011 |
Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.
Topics: 2',5'-Oligoadenylate Synthetase; Antiviral Agents; Chemokine CXCL10; Cyclopropanes; Hepatitis C, Chronic; Humans; Inflammation; Isoindoles; Lactams; Lactams, Macrocyclic; Liver; Neopterin; Proline; RNA, Viral; Sulfonamides | 2011 |
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Thiazoles; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2011 |
Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
Topics: Amino Acid Substitution; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Molecular; Molecular Typing; Mutation; Proline; Protease Inhibitors; Protein Structure, Tertiary; Recombinant Proteins; Recurrence; RNA, Viral; Species Specificity; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Viral Proteins; Virus Replication | 2012 |
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Topics: Antiviral Agents; Australia; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Isoindoles; Kinetics; Lactams; Lactams, Macrocyclic; Models, Biological; Models, Statistical; New Zealand; Phenotype; Polymorphism, Single Nucleotide; Proline; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sulfonamides; Young Adult | 2012 |
Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
Topics: Adult; Antiviral Agents; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Mutation; Placebos; Proline; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins | 2012 |
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome | 2013 |
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Viral Nonstructural Proteins | 2013 |
410 other study(ies) available for proline and Chronic Hepatitis C
| Article | Year |
|---|---|
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2021 |
Successful treatment of Japanese hemophilia patient co-infected with HIV and HCV genotype 4a by glecaprevir/pibrentasvir therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome | 2022 |
Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; China; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Male; Persistent Infection; Phylogeny; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2022 |
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2022 |
Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Inflammation Mediators; Proline; Quinoxalines | 2022 |
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome | 2022 |
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome | 2022 |
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Prospective Studies; Ribavirin; Ritonavir; Romania; Sulfonamides; Uracil; Valine | 2022 |
Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Patient Reported Outcome Measures; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Sulfonamides | 2022 |
Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides | 2022 |
Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Phylogeny; Proline; Pyrrolidines; Quinoxalines; Scotland; Substance Abuse, Intravenous; Sulfonamides | 2022 |
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Proline; Quinoxalines; Registries; Sustained Virologic Response; Taiwan | 2023 |
Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Proline; Quinoxalines; Sustained Virologic Response | 2023 |
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Ribavirin; Ritonavir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2019 |
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2019 |
A novel molecular mechanism to explain mutations of the HCV protease associated with resistance against covalently bound inhibitors.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Molecular; Mutation; Proline; Protease Inhibitors; Viral Nonstructural Proteins | 2019 |
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Comorbidity; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Young Adult | 2019 |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Asia, Eastern; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Taiwan | 2020 |
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Proline; Ribavirin; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2020 |
Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection.
Topics: Adolescent; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Hepatitis C and Compensated Cirrhosis Drug Approved for Eight-Week Treatment.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Approval; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; United States | 2020 |
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Lupus Erythematosus, Systemic; Male; Middle Aged; Proline; Prospective Studies; Renal Insufficiency, Chronic; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cohort Studies; Cyclopropanes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Multicenter Studies as Topic; Proline; Propensity Score; Pyrrolidines; Quinoxalines; Severity of Illness Index; Sulfonamides; Time Factors | 2020 |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Statistics, Nonparametric; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Young Adult | 2019 |
Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C.
Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2020 |
Successful treatment with glecaprevir/pibrentasvir for chronic hepatitis C complicated by primary biliary cholangitis.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis, Biliary; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Azerbaijan; Cyclopropanes; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine | 2020 |
Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter?
Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter? Authors' reply.
Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Databases, Factual; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; United States | 2020 |
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2020 |
Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Cyclopropanes; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine; Young Adult | 2020 |
Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Heart Transplantation; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome; Viremia | 2020 |
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Tablets; Uracil; Valine | 2020 |
The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?
Topics: Aged; Anilides; Antiviral Agents; Benzimidazoles; Blood Glucose; Cholesterol; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Lactams, Macrocyclic; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Triglycerides; Valine | 2020 |
Sustained virological response following an 11-day course of direct acting antiviral therapy for hepatitis C infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactams, Macrocyclic; Middle Aged; Proline; Ritonavir; Simvastatin; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response | 2020 |
Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Topics: Antiviral Agents; Cause of Death; Disease Progression; Female; France; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Mortality; Oligopeptides; Proline; Substance-Related Disorders; Sustained Virologic Response | 2021 |
Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2021 |
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Republic of Korea; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency; Sulfonamides | 2020 |
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response | 2022 |
More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Peritoneal Dialysis; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Sulfonamides | 2020 |
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2021 |
Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2020 |
Letter: now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority.
Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Letter: now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority-authors' reply.
Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides | 2021 |
Hepatitis C and beta-thalassemia major in children: experience with glecaprevir/pibrentasvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Child; China; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Transplantation; Living Donors; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Tacrolimus; Uremia | 2021 |
Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Male; Middle Aged; Precipitating Factors; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Taiwan; Uracil; Valine | 2020 |
Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland.
Topics: Adult; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Switzerland | 2021 |
Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results.
Topics: Adult; Age Distribution; Aged; Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Italy; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response | 2021 |
Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Registries; Sulfonamides; Sustained Virologic Response | 2021 |
Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.
Topics: Aged; Anilides; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Turkey; Valine | 2020 |
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Canada; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Registries; Salvage Therapy; Sofosbuvir; Sulfonamides | 2021 |
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Mutation; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Viral Nonstructural Proteins | 2021 |
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2021 |
Effectiveness of 8- and 12-Week Treatment with Ombitasvir/ Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve HCV Patients in a Real-Life Setting in Romania: the AMETHYST Study.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Romania; Sulfonamides; Time Factors; Uracil; Valine | 2021 |
Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Registries; Sulfonamides; Sustained Virologic Response | 2021 |
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Medication Therapy Management; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection.
Topics: Adult; Anilides; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine | 2021 |
Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
Topics: Adult; Antiviral Agents; China; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides | 2022 |
Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Tacrolimus; Transplant Recipients | 2021 |
Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2017 |
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ireland; Male; Middle Aged; Oligopeptides; Proline; Propensity Score; Prospective Studies; Registries; Ribavirin; Treatment Outcome; Uncertainty | 2017 |
Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon-alpha; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.
Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Risk Factors; Sofosbuvir | 2017 |
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
Topics: Amino Acid Substitution; Antiviral Agents; Bayes Theorem; Carrier Proteins; Cohort Studies; Databases, Genetic; Drug Resistance, Viral; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Protease Inhibitors; RNA, Viral; Viral Nonstructural Proteins | 2017 |
The Influence of Hepatitis C Virus Therapy on the DNA Base Excision Repair System of Peripheral Blood Mononuclear Cells.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cell Nucleus; Cyclopropanes; Deoxyuridine; DNA; DNA Breaks, Double-Stranded; DNA Glycosylases; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Therapy, Combination; Endonucleases; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Lactams, Macrocyclic; Leukocytes, Mononuclear; Macrocyclic Compounds; Mitochondria; Molecular Mimicry; Primary Cell Culture; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fluorenes; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Lipids; Macrocyclic Compounds; Male; Middle Aged; Mutation; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Valine; Young Adult | 2017 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
Topics: 2-Naphthylamine; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Postoperative Period; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
Topics: 2-Naphthylamine; Aged; Anilides; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load | 2017 |
Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals.
Topics: Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Viremia; Virus Activation | 2018 |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Safety; Sulfonamides; Taiwan; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Area Under Curve; Asian People; Benzimidazoles; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Half-Life; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; White People | 2017 |
Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.
Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Drug Monitoring; Female; Fluorescent Antibody Technique, Indirect; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Treatment Outcome | 2017 |
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Propensity Score; Proportional Hazards Models; Ritonavir; Sofosbuvir; Sulfonamides; Survival Rate; Sustained Virologic Response; Uracil; Valine | 2017 |
Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Peritoneal Dialysis; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Mavyret and Vosevi--two new combinations for chronic HCV infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2017 |
Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Bile Acids and Salts; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Pruritus; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Insulin Resistance; Insulin-Secreting Cells; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2017 |
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Placebos; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Surveys and Questionnaires; Sustained Virologic Response | 2018 |
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Self Report; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2018 |
Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Plasma; Proline; Ritonavir; RNA, Viral; Sulfonamides; Valine; Viral Load | 2018 |
Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success.
Topics: Adaptive Immunity; Antibodies, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Immunologic Memory; Interferon-alpha; Longitudinal Studies; Lymphocyte Activation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; T-Box Domain Proteins; Treatment Outcome | 2018 |
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Case-Control Studies; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Hydroxycholesterols; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sex Factors; Sulfonamides; Treatment Failure; Valine | 2018 |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; Saudi Arabia; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2017 |
Beyond one virus: vaccination against hepatitis B after hepatitis C treatment.
Topics: Adult; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Expeditions; Genotype; Hepatitis B; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Vaccination | 2018 |
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.
Topics: 2-Naphthylamine; Aged; Amino Acid Substitution; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoenzymes; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Recurrence; Ribavirin; Sulfonamides; Treatment Failure; Uracil; Valine; Viral Load; Viral Nonstructural Proteins | 2018 |
Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Humans; Male; Models, Molecular; Molecular Dynamics Simulation; Mutation, Missense; Polymorphism, Genetic; Proline; Recurrence; Treatment Failure; Valine; Viral Nonstructural Proteins | 2018 |
A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Myositis, Inclusion Body; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine | 2018 |
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Topics: 2-Naphthylamine; Anilides; Antihypertensive Agents; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Insufficiency; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2018 |
The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Valine | 2018 |
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Retreatment of hepatitis C virus: can it get any better?
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2018 |
Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Proline; Ritonavir; Sirolimus; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Uridine Monophosphate; Valine | 2018 |
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
Topics: 2-Naphthylamine; Aged; Anilides; Antineoplastic Agents; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sorafenib; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Valine; Virus Activation | 2019 |
Chinese approval for Ascletis' HCV drug is first homegrown success.
Topics: Antiviral Agents; Biotechnology; China; Cyclopropanes; Drug Approval; Government Agencies; Hepatitis C, Chronic; Humans; Investments; Isoindoles; Lactams; Lactams, Macrocyclic; Proline; Sulfonamides; Virus Replication | 2018 |
Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
Topics: Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Failure; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Salvage Therapy; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Risk Factors; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Spain; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Viral Load; Young Adult | 2019 |
Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.
Topics: Adult; Aged, 80 and over; Algorithms; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Valine | 2019 |
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Phylogeny; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Viral Nonstructural Proteins | 2018 |
The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Agammaglobulinemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genetic Diseases, X-Linked; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunoglobulin G; Immunoglobulins, Intravenous; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2019 |
Glecaprevir/Pibrentasvir (Mavyret) for the Treatment of Chronic Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2018 |
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Proline; Qualitative Research; Ribavirin; Ritonavir; RNA, Viral; Substance Abuse, Intravenous; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation.
Topics: Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Jaundice, Obstructive; Lactams, Macrocyclic; Leucine; Male; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency; Sulfonamides | 2019 |
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Protease Inhibitors; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult | 2018 |
Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Contraindications, Drug; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
Topics: Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Dialysis; Retreatment; Sulfonamides; Treatment Failure; Valine | 2019 |
NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Sequence Deletion; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2019 |
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Observational Studies as Topic; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ritonavir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine | 2019 |
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Insufficiency, Chronic; Retrospective Studies; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors; Ritonavir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2019 |
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sulfonamides; Viral Nonstructural Proteins | 2019 |
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studi
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Internationality; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; Female; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Recovery of Function; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load; Young Adult | 2019 |
Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest?
Topics: Adult; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Transaminases; Treatment Outcome; Uracil; Valine | 2019 |
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
Topics: Adult; Anemia; Anilides; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2022 |
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antidepressive Agents; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Mental Disorders; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Adherence and Compliance; Young Adult | 2019 |
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome | 2019 |
5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.
Topics: Alkaloids; Antiviral Agents; Cell Line, Tumor; Cell Survival; Drug Synergism; Drug Therapy, Combination; HEK293 Cells; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Indolizines; Interferon-alpha; Phenanthrenes; Primary Cell Culture; Proline; Sofosbuvir; Tetraspanin 28; Tylophora; Viral Envelope Proteins; Virus Internalization | 2019 |
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Proline; Prospective Studies; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
[EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN PATIENTS WITH HCV 1B GENOTYPE INFECTION: REAL WORLD DATA].
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Ukraine; Uracil; Valine | 2019 |
Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective.
Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Oligopeptides; Proline; Public Health Practice; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome | 2019 |
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Substance Abuse, Intravenous; Sulfonamides; Sustained Virologic Response; Young Adult | 2019 |
Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Leucine; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Markov Chains; Proline; Quinoxalines; Sofosbuvir; State Medicine; Sulfonamides; United Kingdom | 2019 |
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cyclopropanes; Hepatectomy; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Middle Aged; Neoplasm Recurrence, Local; Proline; Prospective Studies; Radiofrequency Ablation; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2019 |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Taiwan | 2019 |
Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Egypt; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Renal Dialysis; Ritonavir; Sulfonamides; Treatment Outcome; Valine | 2019 |
Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Proline; Pyrrolidines; Quinoxalines; Recurrence; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome | 2019 |
A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy.
Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Models, Molecular; Molecular Sequence Data; Phylogeny; Proline; Protease Inhibitors; Treatment Failure; Viral Nonstructural Proteins | 2013 |
The FDA, bridging data, and hepatitis C.
Topics: Antiviral Agents; Drug Approval; Drug Monitoring; Hepatitis C, Chronic; Humans; Oligopeptides; Proline | 2013 |
Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies.
Topics: Adolescent; Adult; Albumins; Antiviral Agents; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Endpoint Determination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load | 2013 |
Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Treatment Outcome; Veterans; Viral Load | 2013 |
What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.
Topics: Antiviral Agents; Developing Countries; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Pakistan; Proline | 2013 |
A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Topics: Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States | 2013 |
Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Treatment Outcome; Viral Load; Young Adult | 2013 |
Telaprevir and boceprevir: a potential role for therapeutic drug monitoring.
Topics: Antiviral Agents; Area Under Curve; Drug Monitoring; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors | 2013 |
Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Life Expectancy; Male; Middle Aged; Oligopeptides; Proline; Quality of Life; Ribavirin; Survival Analysis; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans Health | 2013 |
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Oligopeptides; Proline; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Failure | 2013 |
Boceprevir for HCV in patients with HIV: where next?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment.
Topics: Antiviral Agents; Drug Eruptions; Drug Hypersensitivity Syndrome; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Severity of Illness Index | 2013 |
Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Drug Prescriptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Time Factors | 2013 |
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.
Topics: Amino Acid Substitution; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Mutation, Missense; Proline; Treatment Failure; Viral Nonstructural Proteins | 2013 |
Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.
Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Treatment Outcome | 2013 |
[Therapy of hepatitis C: new inhibitors as hammers against HCV].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Oligopeptides; Proline; Protease Inhibitors | 2013 |
Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
Topics: Age Factors; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Markov Chains; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Spain | 2013 |
Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.
Topics: Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Renal Insufficiency | 2014 |
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2014 |
Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.
Topics: Adult; Antiviral Agents; Drug Interactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
New triple therapy for chronic hepatitis C: real life clinical experience in a community setting.
Topics: Antiviral Agents; Community Health Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Retrospective Studies; Ribavirin; Viral Load | 2013 |
Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation.
Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Methylprednisolone; Polyethylene Glycols; Proline; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load | 2014 |
HCV, ribavirin, and anemia: a new dawn.
Topics: Anemia; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
From the CUPIC study: great times are not coming (?).
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Oligopeptides; Proline | 2014 |
Reply to: From the CUPIC study: great times are not coming (?).
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Oligopeptides; Proline | 2014 |
Reply: To PMID 23873583.
Topics: Contraindications; Female; Hepatitis C, Chronic; Humans; Male; Proline; Protease Inhibitors | 2014 |
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Decision Making; Disease Progression; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Time Factors; Watchful Waiting | 2014 |
The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors | 2013 |
Reply: To PMID 23813604.
Topics: Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Renal Insufficiency | 2014 |
Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role?
Topics: Adult; Antiviral Agents; Carrier Proteins; Drug Interactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Seizures; Viral Nonstructural Proteins | 2013 |
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Monitoring; Drug Resistance, Viral; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Mutation; Oligopeptides; Polymorphism, Genetic; Proline; Protease Inhibitors; Quinolines; Thiazoles; Viral Nonstructural Proteins | 2014 |
Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prognosis; Proline; Retrospective Studies; Withholding Treatment | 2014 |
The dilemma for patients with chronic hepatitis C: treat now or warehouse?
Topics: Antiviral Agents; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors; Watchful Waiting | 2014 |
First case of drug rash eosinophilia and systemic symptoms due to boceprevir.
Topics: Antiviral Agents; Drug Hypersensitivity Syndrome; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Middle Aged; Proline; Risk Factors; Serine Proteinase Inhibitors | 2014 |
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Ribavirin | 2014 |
Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Treatment Outcome; United States; Veterans | 2014 |
From the CUPIC study: great times are not coming(?).
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Oligopeptides; Proline | 2014 |
Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir.
Topics: Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Renal Insufficiency | 2014 |
Reply: To PMID 23813604.
Topics: Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Renal Insufficiency | 2014 |
Reply to: "From the CUPIC study: great times are not coming(?)".
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Oligopeptides; Proline | 2014 |
Failed triple therapy in a treatment-experienced patient with genotype 6 hepatitis C infection.
Topics: Aged; Antiviral Agents; Diagnostic Errors; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure; United States; Vietnam; Viral Load | 2014 |
[Boceprevir and telaprevir utilization: evaluation for the treatment of chronic hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Treatment Outcome | 2014 |
FDA bridging analyses confirmed in clinical trial.
Topics: Antiviral Agents; Drug Approval; Drug Monitoring; Hepatitis C, Chronic; Humans; Oligopeptides; Proline | 2014 |
Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Viral Nonstructural Proteins | 2014 |
Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline | 2014 |
Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; End Stage Liver Disease; Female; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kidney; Kidney Function Tests; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load | 2014 |
Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach.
Topics: Contraindications; Female; Hepatitis C, Chronic; Humans; Male; Proline; Protease Inhibitors | 2014 |
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Middle Aged; Models, Economic; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome | 2014 |
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Severity of Illness Index | 2014 |
[Treatment of hepatitis C infection. A revolution should not hide another].
Topics: Antiviral Agents; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Risk Reduction Behavior | 2014 |
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Quality-Adjusted Life Years; Sofosbuvir; Uridine Monophosphate | 2014 |
Letter to the editor.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin | 2014 |
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2014 |
HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyper-IgM Immunodeficiency Syndrome; Imidazoles; Immunoglobulin M; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine | 2014 |
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate | 2014 |
Therapy of hepatitis C--back to the future.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Sulfonamides; Valine | 2014 |
Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.
Topics: Adult; Antiviral Agents; Austria; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2014 |
Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
Topics: Antiviral Agents; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin | 2014 |
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Cutaneous side-effects of antihepatitis C treatment: the U.K. experience.
Topics: Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; United Kingdom | 2015 |
Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Middle Aged; Oligopeptides; Proline; Prospective Studies | 2015 |
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Plasma; Proline; Ribavirin; Treatment Failure; Viral Load; Viral Nonstructural Proteins; Young Adult | 2014 |
Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Evolution, Molecular; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Sequence Analysis, RNA; Viral Nonstructural Proteins | 2014 |
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Multivariate Analysis; National Health Programs; Polyethylene Glycols; Proline; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Decision Trees; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Statistical; Proline; Reproducibility of Results; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Young Adult | 2014 |
Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2014 |
[Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment].
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors | 2015 |
Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Porphyria Cutanea Tarda; Proline; Remission Induction | 2014 |
Effectiveness research in the evolving HCV landscape.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline | 2014 |
Not so sweet: autoimmune diabetes mellitus on triple therapy for chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Ribavirin; Young Adult | 2015 |
Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
"Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors | 2014 |
Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome | 2014 |
Risky business-the real life of the unresolved HCV therapy.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Oligopeptides; Proline | 2014 |
What is the contribution of protease inhibitors to the high mortality of patients with cirrhosis receiving HCV treatment?
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Oligopeptides; Proline | 2014 |
Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline | 2015 |
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load | 2015 |
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prisoners; Proline; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience.
Topics: Decision Making; Drug Therapy, Combination; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Italy; Male; Middle Aged; Oligopeptides; Precision Medicine; Proline; Treatment Outcome | 2014 |
Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infect
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Recurrence; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Load | 2015 |
Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2015 |
Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
Topics: Adult; Antiviral Agents; Coinfection; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2015 |
Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Topics: Antiviral Agents; Drug Monitoring; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Proline; Recombinant Proteins; Ribavirin; Signal Transduction; Treatment Outcome | 2014 |
Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans.
Topics: Antiviral Agents; Drug Therapy, Combination; Drug Utilization; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States; Veterans | 2015 |
Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
Topics: Aged; Antiviral Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Veterans | 2015 |
Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
Topics: Aged; Anemia; Antiviral Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Oligopeptides; Proline; RNA, Viral; Thrombocytopenia; Treatment Outcome; Viral Load | 2015 |
Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin | 2015 |
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prognosis; Proline; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA; Viral Load | 2015 |
Dermatitis induced by first-generation hepatitis C virus protease inhibitors.
Topics: Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Protease Inhibitors | 2015 |
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Topics: Anemia; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; France; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Plasma; Proline; Prospective Studies; Ribavirin; Treatment Failure | 2015 |
Probable boceprevir-induced hyponatremia in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hyponatremia; Interferon-alpha; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2015 |
Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Mutation; Oligopeptides; Polymerase Chain Reaction; Polymorphism, Genetic; Prevalence; Proline; Scotland; Sequence Analysis, DNA; Simeprevir; Viral Nonstructural Proteins | 2015 |
Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.
Topics: Antiviral Agents; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Practice Patterns, Physicians'; Proline; Retrospective Studies; United States | 2015 |
Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2015 |
First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies | 2015 |
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.
Topics: Adult; Coinfection; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome | 2015 |
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
Topics: Antiviral Agents; Clinical Decision-Making; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Spain; Treatment Outcome; Viral Load; Viremia | 2015 |
Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Tertiary Care Centers; Treatment Outcome; Viral Load | 2015 |
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; Depressive Disorder; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Male; Mianserin; Middle Aged; Mirtazapine; Physician's Role; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Genotype; Greece; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Markov Chains; Models, Econometric; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sensitivity and Specificity | 2015 |
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Incidence; Male; Membrane Transport Proteins; Middle Aged; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Pyrophosphatases; Ribavirin; Risk Assessment; Young Adult | 2015 |
Thousands of patients in England to get new hepatitis C drugs.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; England; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythrocyte Indices; Erythrocyte Membrane; Erythropoiesis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Pyrophosphatases; Ribavirin; Treatment Outcome | 2016 |
Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
Topics: Adult; Aged; Anemia; Antiviral Agents; Databases, Factual; Drug Costs; Drug Eruptions; Drug Therapy, Combination; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; United States | 2015 |
Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
Topics: Adult; Antiviral Agents; Belgium; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2016 |
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; HIV Infections; Humans; Leucine; Male; Middle Aged; Oligopeptides; Patient Acceptance of Health Care; Proline; Prospective Studies; Protease Inhibitors; Quinolines; RNA, Viral; Switzerland; Thiazoles; Viral Load | 2015 |
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2015 |
Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer?
Topics: Aged; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Ribavirin; Surveys and Questionnaires; White People | 2016 |
[High chance for cure].
Topics: 2-Naphthylamine; Anilides; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Random Allocation; Ribavirin; Treatment Outcome; Viral Load | 2015 |
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Proline; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2015 |
Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
Topics: Antiviral Agents; Asia; Asian People; Australia; Biomarkers; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proline; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load; White People | 2015 |
T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.
Topics: Adult; Aged; Amides; Antiviral Agents; Apoptosis; Benzofurans; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Lipopolysaccharides; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Quinoxalines; Recombinant Proteins; Ribavirin; Sulfonamides | 2015 |
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sustained Virologic Response | 2015 |
[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hematologic Diseases; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Remission Induction; Retrospective Studies; Ribavirin; Spain | 2015 |
Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Opiate Substitution Treatment; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2015 |
Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Raltegravir Potassium; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Futility; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Treatment Outcome | 2015 |
Does boceprevir really increase the risk of skin eruptions during antihepatitis C treatment?
Topics: Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Protease Inhibitors | 2016 |
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin | 2016 |
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load | 2016 |
Reply to: Clinical and immunological findings in 104 cases of paraneoplastic pemphigus.
Topics: Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Protease Inhibitors | 2016 |
Development and persistence of DAA resistance associated mutations in patients failing HCV treatment.
Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Mutation, Missense; Oligopeptides; Proline; Sequence Analysis, DNA; Treatment Failure; Viral Nonstructural Proteins | 2015 |
Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Glycyrrhizic Acid; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ritonavir; Sulfonamides; Ursodeoxycholic Acid; Valine; Young Adult | 2015 |
Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Young Adult | 2015 |
Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Intraocular pressure rise in the course of peginterferon alpha-2a, ribavirin, and boceprevir therapy for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Gonioscopy; Hepatitis C, Chronic; Humans; Interferon-alpha; Intraocular Pressure; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Tonometry, Ocular; Viral Load; Visual Fields | 2015 |
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
Topics: Anemia; beta 2-Glycoprotein I; Drug Therapy, Combination; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Pyrophosphatases; Treatment Outcome | 2015 |
Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.
Topics: Adult; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Mutation, Missense; Proline; Protease Inhibitors; RNA, Viral; Sequence Analysis, DNA; Simeprevir; Sulfonamides; Viral Nonstructural Proteins | 2016 |
Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Female; Gene Expression Profiling; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Liver; Macrophages; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Staining and Labeling | 2016 |
'Reply to: Clinical and immunological findings in 104 cases of paraneoplastic pemphigus': reply from the authors.
Topics: Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Protease Inhibitors | 2016 |
[Vaniprevir with pegylated interferon and ribavirin in treatment for chronic hepatitis C].
Topics: Clinical Trials as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Indoles; Interferons; Isoindoles; Lactams, Macrocyclic; Leucine; Proline; Ribavirin; Sulfonamides | 2015 |
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Veterans | 2016 |
Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Treatment Failure; Viral Load | 2016 |
[Resistance to protease inhibitors and efficiency of antiviral therapy in patients with chronic hepatitis C].
Topics: Adult; Aged; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Simeprevir; Young Adult | 2016 |
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Topics: 2-Naphthylamine; Anilides; Antacids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Hydrogen-Ion Concentration; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2016 |
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.
Topics: Anemia; Antiviral Agents; Coinfection; Decision Support Techniques; Drug Therapy, Combination; Female; Genotyping Techniques; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Male; Membrane Transport Proteins; Oligopeptides; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Proline; Ribavirin | 2016 |
Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
Topics: Algorithms; Antiviral Agents; Cell Line; Drug Resistance, Viral; Genetic Association Studies; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Internet; Mutation; Oligopeptides; Phenotype; Proline; Simeprevir; Software | 2016 |
Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Mutation; Polymerase Chain Reaction; Proline; Treatment Outcome; Viral Nonstructural Proteins | 2016 |
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2016 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine | 2016 |
Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.
Topics: Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Economic; Proline; Ritonavir; Sulfonamides; Valine | 2016 |
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Statistics, Nonparametric; Sustained Virologic Response; Time Factors; Treatment Failure; Young Adult | 2016 |
Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection.
Topics: 2-Naphthylamine; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Withholding Treatment | 2016 |
Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Oligopeptides; Proline; Protease Inhibitors; Simeprevir; Turkey; Viral Nonstructural Proteins; Young Adult | 2016 |
Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Topics: Acrylates; Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Leucine; Mutation; Oligopeptides; Polymorphism, Genetic; Proline; Protease Inhibitors; Quinolines; Thiazoles; Treatment Outcome; Viral Nonstructural Proteins | 2016 |
Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerations.
Topics: Antiviral Agents; Cyclopropanes; Hepatitis C; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Biological; Proline; Sulfonamides | 2016 |
Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Proline; Quality of Life; Retrospective Studies; Ribavirin; Treatment Outcome | 2017 |
Ombitasvir-Paritaprevir-Ritonavir-Dasabuvir (Viekira Pak)-Induced Lactic Acidosis.
Topics: 2-Naphthylamine; Acidosis, Lactic; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Fluid Therapy; Hemofiltration; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Respiration, Artificial; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uracil; Valine; Viral Nonstructural Proteins | 2017 |
Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Industry; Drug Therapy, Combination; Fees, Pharmaceutical; Fluorenes; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Quality Assurance, Health Care; Quality Control; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2016 |
Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report.
Topics: 2-Naphthylamine; Anilides; Anticoagulants; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Warfarin | 2017 |
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hong Kong; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Uracil; Valine | 2017 |
Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.
Topics: 2-Naphthylamine; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dengue; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load | 2016 |
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
Topics: Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Proline; RNA, Viral; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Young Adult | 2017 |
A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis.
Topics: 2-Naphthylamine; Aged, 80 and over; Anilides; Antiviral Agents; Ascites; Carbamates; Chemical and Drug Induced Liver Injury; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Liver Cirrhosis; Liver Failure, Acute; Liver Function Tests; Macrocyclic Compounds; Male; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2016 |
Combination Therapy with Ombitasvir/Paritaprevir/Ritonavir for Dialysis Patients Infected with Hepatitis C Virus: A Prospective Multi-Institutional Study.
Topics: Aged; Anilides; Carbamates; Cyclopropanes; Demography; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ritonavir; Sulfonamides; Valine | 2017 |
The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Germany; Hepatitis C, Chronic; Humans; Incidence; Insurance, Health; Male; Middle Aged; Oligopeptides; Prevalence; Proline; Retrospective Studies | 2017 |
Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Prevalence; Proline; Retreatment; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load | 2017 |
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Anilides; Anti-HIV Agents; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Seropositivity; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2017 |
Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; British Columbia; Cohort Studies; Female; Healthcare Disparities; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Young Adult | 2017 |
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Neoplasm Recurrence, Local; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult | 2017 |
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ritonavir; Severity of Illness Index; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2009 |
STAT-C: a full revolution or just a step forward?
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Virus Replication | 2010 |
Curing hepatitis C with pills: a step toward global control.
Topics: Administration, Oral; Antiviral Agents; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Proline; Sulfonamides; Viral Nonstructural Proteins | 2010 |
Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents.
Topics: Animals; Antiviral Agents; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Pan troglodytes; Proline; Protease Inhibitors; Sulfonamides; Treatment Outcome; Tubercidin; Viral Load; Viral Nonstructural Proteins | 2011 |
A new era of hepatitis C therapy begins.
Topics: Anemia; Antiviral Agents; Black People; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors | 2011 |
Infectious diseases. First specific drugs raise hopes for hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Developing Countries; Drug Approval; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins | 2011 |
Perspective: miles to go before we sleep.
Topics: Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Time Factors | 2011 |
Two drugs approved for chronic hepatitis C infection.
Topics: Antiviral Agents; Drugs, Investigational; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors | 2011 |
The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Medication Adherence; Oligopeptides; Proline | 2012 |
Boceprevir for chronic HCV genotype 1 infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin | 2011 |
Boceprevir for chronic HCV genotype 1 infection.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2011 |
HCV protease inhibitors bring new options for patients.
Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Virus Replication | 2011 |
Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Topics: Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2011 |
[Studies with boceprevir].
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Proline; Recurrence; RNA, Viral | 2011 |
[A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Precision Medicine; Proline; Protease Inhibitors | 2011 |
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
Topics: Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Prognosis; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Societies, Medical; Treatment Outcome; United States | 2011 |
[New triple therapy in chronic hepatitis C. Increased patient chances].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; RNA, Viral | 2011 |
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Crystallography, X-Ray; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Kinetics; Leucine; Mutagenesis, Site-Directed; Mutation Rate; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Quinolines; Replicon; Thiazoles; Viral Nonstructural Proteins | 2012 |
Interferon-free treatment regimens for hepatitis C: are we there yet?
Topics: Aminoisobutyric Acids; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Oligopeptides; Proline; Quinolines; Ribavirin; RNA-Dependent RNA Polymerase; Thiazoles | 2011 |
The expanding role of the pharmacist in the management of hepatitis C infection.
Topics: Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Protease Inhibitors | 2011 |
Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
Topics: Antiviral Agents; Biomarkers; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Decision Making; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Predictive Value of Tests; Proline; Retrospective Studies; RNA, Viral; Treatment Outcome | 2012 |
Boceprevir.
Topics: Antiviral Agents; Biopsy; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Liver; Polymorphism, Genetic; Proline; Serine Proteinase Inhibitors; Viral Load | 2011 |
Protease inhibitors in hepatitis C: from chronic disease to cure.
Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors | 2011 |
New HCV drugs trigger race for more tolerable therapies.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Industry; Drug Resistance, Multiple, Viral; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline | 2011 |
Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.
Topics: Antiviral Agents; Genotype; Guidelines as Topic; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Oligopeptides; Proline; Protease Inhibitors; United States | 2012 |
A major advance in treating hepatitis C.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Approval; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; United States; United States Food and Drug Administration | 2011 |
New developments in HCV therapy.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
Direct-acting antiviral (DAA) actions in treatment-naïve patients.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors | 2011 |
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; United Kingdom; Viral Load | 2012 |
[Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2012 |
[Current indications for triple therapy in hepatitis C virus infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2012 |
Triple therapy for hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Oligopeptides; Proline | 2012 |
[New times for the treatment of chronic hepatitis C].
Topics: Antiviral Agents; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Virus Replication | 2012 |
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
Topics: Cost-Benefit Analysis; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline | 2012 |
Boceprevir.
Topics: Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Proline; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2012 |
Targeted therapies for hepatitis C reach the clinic.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline | 2012 |
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.
Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Risk Factors | 2012 |
Genetic factors and hepatitis C virus infection.
Topics: Antiviral Agents; Gene Frequency; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proline; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2012 |
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].
Topics: Antiviral Agents; Biopsy; Contraindications; Diagnostic Imaging; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon Type I; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Patient Care Team; Polyethylene Glycols; Proline; Protease Inhibitors; Recurrence; Ribavirin; Viral Load | 2012 |
New genetic discoveries and treatment for hepatitis C.
Topics: Antiviral Agents; DNA, Viral; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Proline; Recombinant Proteins; Ribavirin | 2012 |
Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon-alpha; Proline; Ribavirin; United States | 2013 |
Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2012 |
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Databases, Factual; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure | 2012 |
Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; MicroRNAs; Oligopeptides; Proline; Protease Inhibitors; Treatment Outcome; Viral Nonstructural Proteins; Virus Replication | 2012 |
Effect of discounting on estimation of benefits determined by hepatitis C treatment.
Topics: Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Markov Chains; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin | 2012 |
Clinical relevance of detectable hepatitis C virus RNA in the context of direct-acting antivirals.
Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; RNA, Viral | 2013 |
Reply: To PMID 22095516.
Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; RNA, Viral | 2013 |
Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers.
Topics: Antiviral Agents; Black or African American; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Research Subjects; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Failure | 2012 |
Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
Topics: Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors | 2012 |
Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.
Topics: Aged; Antiviral Agents; Cyclosporine; Disease Management; Drug Therapy, Combination; Everolimus; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sirolimus; Tacrolimus; Viral Load | 2012 |
[Treatment of chronic hepatitis C in HIV coinfection].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Oligopeptides; Proline; Serine Proteinase Inhibitors | 2012 |
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Failure | 2012 |
HIV protease inhibitors in combination with boceprevir: are drug-drug interactions the same for all patients?
Topics: Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Proline; Viral Load | 2012 |
[Treatment of chronic hepatitis viral C: new associations].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2012 |
The changing face of hepatitis C in the new era of direct-acting antivirals.
Topics: Antiviral Agents; Asymptomatic Diseases; Carrier State; Health Services Accessibility; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Treatment Outcome | 2013 |
Telaprevir to boceprevir switch highlights lack of cross-reactivity.
Topics: Antiviral Agents; Cross Reactions; Drug Substitution; Eosinophilia; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; RNA, Viral; Viral Load | 2013 |
[Prevalence of potential interactions between antiretroviral therapy and boceprevir or telaprevir in human immunodeficiency virus-hepatitis C virus coinfected patients].
Topics: Adult; Aged; Anti-Retroviral Agents; Coinfection; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies | 2013 |
Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials, Phase II as Topic; Coinfection; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Oligopeptides; Proline; Treatment Outcome | 2012 |
Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Ribavirin | 2012 |
[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
Topics: Antiviral Agents; Drug Approval; Drug Design; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-Stimulated Gene Factor 3, gamma Subunit; Oligopeptides; Proline | 2012 |
Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Portugal; Proline; Recombinant Proteins; Ribavirin | 2013 |
Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Limit of Detection; Oligopeptides; Proline; Retrospective Studies; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
Topics: Adult; Amino Acid Sequence; Base Sequence; Carbamates; DNA, Viral; Drug Resistance, Viral; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Macrocyclic Compounds; Male; Molecular Sequence Data; Oligopeptides; Point Mutation; Proline; Quinolines; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Serine Endopeptidases; Serine Proteinase Inhibitors; Thiazoles; Viral Nonstructural Proteins | 2008 |